ANG2 / VEGF ANTIBODIES AND USES THEREOF

Abstract

Described herein are antibodies that bind to VEGF_A or ANG-2, or bispecific antibodies that bind to VEGF_A and ANG-2. The antibodies of the present disclosure are useful for treating eye diseases, including macular degeneration.

Description

[Technical Field]

[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 63 / 388,538, filed July 12, 2022, which is incorporated herein by reference. [Background technology]

[0002] Eye diseases, including macular degeneration and retinal vein occlusion, affect thousands of individuals each year and can result in permanent vision loss or blindness. The proteins vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2) influence the development of these diseases and therefore serve as potential therapeutic targets. Summary of the Invention

[0003] Described herein are antibodies and bispecific antibodies that bind to VEGF and / or ANG-2. Also described are methods for treating ocular diseases by administering the antibodies and bispecific antibodies to an individual in need thereof. Such diseases include macular degeneration, retinal vein occlusion, branch vein occlusion, and central vein occlusion. The bispecific antibodies described herein have an advantage over previously described bispecific antibodies in that the binding moieties that bind to VEGF and ANG-2 both bind to their respective antigens with high affinity. Furthermore, the surrogate light chain used as the common light chain is of human germline origin, thus enabling a safer molecule that is less immunogenic than other common light chains and less susceptible to anti-therapeutic antibody responses. A low anti-therapeutic antibody immune response is desirable because it allows therapeutic antibodies to maintain efficacy over repeated administrations.

[0004]

[0010] In one aspect, described herein is a vascular endothelial growth factor (VEGF)-binding antibody or antigen-binding fragment thereof, comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO:3 (GYTFSIYT), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO:4 (INPYNGNT), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO:5 (AKAPAVFWWTGLDY), wherein the antibody binds to VEGF. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:1. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a surrogate light chain. In certain embodiments, the surrogate light chain comprises (a) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS), (b) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK), and (c) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH). In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the antibody binds to a peptide comprising the platelet-derived growth factor (PDGF) domain of VEGF-A.In certain embodiments, the PDGF domain of VEGF_A comprises a fragment of VEGF_A ranging from amino acids 50 to 132. In certain embodiments, the antibody binds to a peptide comprising the VEGF-C heparin domain of VEGF-A. In certain embodiments, the VEGF_C heparin domain of VEGF_A comprises a fragment of VEGF-A ranging from amino acids 143 to 191. In certain embodiments, the antibody binds to VEGF-A or a fragment thereof. In certain embodiments, the antibody binds to VEGF_A or a fragment thereof with an EC50 of about 60 picomolar or less. In certain embodiments, the antibody inhibits the interaction of VEGF-A or a fragment thereof with a VEGF receptor. In certain embodiments, the antibody inhibits the interaction of VEGF_A or a fragment thereof with a VEGF receptor with an IC50 of about 2000 picomolar or less. In certain embodiments, the antibody inhibits the interaction of VEGF_A or a fragment thereof with a VEGF receptor at least three times more potently than faricimab inhibits said interaction. In certain embodiments, the VEGF receptor is VEGF receptor 2 / kinase insert domain receptor (KDR). In certain embodiments, the antibody or antigen-binding fragment thereof is a Fab, F(ab)2, single-domain antibody, or single-chain variable fragment (scFv). In certain embodiments, the antibody or antigen-binding fragment thereof is an IgG antibody. In certain embodiments, the antibody or antigen-binding fragment thereof is human, chimeric, or humanized. In certain embodiments, the antibody or antigen-binding fragment thereof is humanized. Pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, excipient, or diluent are also described. In certain embodiments, the pharmaceutical composition is formulated for intravenous administration. In certain embodiments, the pharmaceutical composition is formulated for intravitreal administration. Nucleic acids encoding the antibodies are also described herein. In certain embodiments, the nucleic acid is an expression vector. In certain embodiments, the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector.In certain embodiments, the expression vector is formulated for intravenous administration. In certain embodiments, the expression vector is formulated for intravitreal administration. Cells comprising a nucleic acid or expression vector are also described herein. In certain embodiments, the cell is a eukaryotic cell suitable for antibody production. In certain embodiments, the bispecific antibody is used in a method for treating an ocular disease in an individual, the method comprising administering to the individual an antibody, a nucleic acid or nucleic acids encoding the antibody, or a pharmaceutical composition comprising the antibody, thereby treating the ocular disease. In certain embodiments, the ocular disease is macular degeneration. In certain embodiments, the macular degeneration is age-related. In certain embodiments, the macular degeneration is diabetes-related. In certain embodiments, the macular degeneration is wet macular degeneration. In certain embodiments, the ocular disease is branch retinal vein occlusion. In certain embodiments, the ocular disease is central retinal vein occlusion.

[0005]

[0010] In one aspect, described herein is an angiopoietin-2 (ANG-2)-binding antibody or antigen-binding fragment thereof, comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY), wherein the antibody binds to ANG-2. In certain embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a surrogate light chain. In certain embodiments, the surrogate light chain comprises (a) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS), (b) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK), and (c) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH). In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the antibody binds to ANG-2. In certain embodiments, the antibody binds to ANG-2 with an EC50 of about 55 picomolar or less.In certain embodiments, the antibody binds to ANG-2 at least 50-fold more strongly than faricimab. In certain embodiments, the antibody inhibits the interaction of ANG-2 with the ANG-2 receptor. In certain embodiments, the antibody inhibits the interaction of ANG-2 with the ANG-2 receptor with an IC50 of about 800 picomolar or less. In certain embodiments, the antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at least 15-fold more strongly than faricimab. In certain embodiments, the ANG-2 receptor is a tyrosine kinase with immunoglobulin-like and EGF-like domain 2 receptor (Tie-2 receptor). In certain embodiments, the antibody or antigen-binding fragment thereof is a Fab, F(ab)2, single-domain antibody, or single-chain variable fragment (scFv). In certain embodiments, the antibody or antigen-binding fragment thereof is an IgG antibody. In certain embodiments, the antibody or antigen-binding fragment thereof is human, chimeric, or humanized. In certain embodiments, the antibody or antigen-binding fragment thereof is humanized. Also described herein are pharmaceutical compositions comprising an antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, excipient, or diluent. In certain embodiments, the pharmaceutical composition is formulated for intravenous administration. In certain embodiments, the pharmaceutical composition is formulated for intravitreal administration. Nucleic acids encoding the antibodies are also described herein. In certain embodiments, the nucleic acid is an expression vector. In certain embodiments, the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector. In certain embodiments, the expression vector is formulated for intravenous administration. In certain embodiments, the expression vector is formulated for intravitreal administration. Also described herein are cells comprising the nucleic acid or expression vector. In certain embodiments, the cell is a eukaryotic cell suitable for producing the antibody. In certain embodiments, the antibody is used in a method for treating an ocular disease in an individual, the method comprising administering to the individual an antibody, a nucleic acid or nucleic acids encoding the antibody, or a pharmaceutical composition comprising the antibody, thereby treating the ocular disease. In certain embodiments, the ocular disease is macular degeneration. In certain embodiments, the macular degeneration is age-related.In certain embodiments, the macular degeneration is diabetes-related. In certain embodiments, the macular degeneration is wet macular degeneration. In certain embodiments, the eye disease is branch retinal vein occlusion. In certain embodiments, the eye disease is central retinal vein occlusion.

[0006] In another aspect, a vascular endothelial growth factor (VEGF) binding moiety is provided, the vascular endothelial growth factor A (VEGF_A) binding moiety comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT); (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT); and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY). Described herein are bispecific antibodies that bind to VEGF_A and ANG-2, comprising an angiopoietin 2 (ANG-2) binding portion comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY). In certain embodiments, the VEGF binding portion comprises a heavy chain variable region comprising an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the VEGF binding portion further comprises a heavy chain constant region. In certain embodiments, the heavy chain constant region comprises an engineered protuberance or an engineered cavity such that homodimerization of the VEGF-binding moiety is inhibited. In certain embodiments, the engineered protuberance comprises a T366W substitution according to EU numbering. In certain embodiments, the engineered cavity comprises a T366S / L368A / Y407V substitution according to EU numbering. In certain embodiments, the heavy chain constant region comprises one or more substitutions in the Fc region that reduce antibody effector function. In certain embodiments, the one or more substitutions in the Fc region that reduce antibody effector function comprise L234A and / or L235A according to EU numbering. In certain embodiments, the heavy chain constant region comprises one or more substitutions of a cysteine residue. In certain embodiments, the one or more substitutions of a cysteine residue are at serine 354 according to EU numbering.In certain embodiments, the VEGF-binding moiety comprises a heavy chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the ANG-2-binding moiety comprises a heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:11. In certain embodiments, the ANG-2-binding moiety further comprises a heavy chain constant region. In certain embodiments, the heavy chain constant region comprises an engineered protuberance or an engineered cavity such that homodimerization of the ANG-2-binding moiety is inhibited. In certain embodiments, the engineered protuberance comprises a T366W substitution according to EU numbering. In certain embodiments, the engineered cavity comprises a T366S / L368A / Y407V substitution according to EU numbering. In certain embodiments, the heavy chain constant region comprises one or more substitutions in the Fc region that reduce antibody effector function. In certain embodiments, the one or more substitutions in the Fc region that reduce antibody effector function comprise L234A and / or L235A according to EU numbering. In certain embodiments, the heavy chain constant region comprises one or more substitutions of a cysteine residue. In certain embodiments, the one or more substitutions of a cysteine residue are at serine 354 according to EU numbering. In certain embodiments, the bispecific antibody binds to a peptide comprising the platelet-derived growth factor (PDGF) domain of VEGF-A. In certain embodiments, the PDGF domain of VEGF_A comprises a fragment of VEGF_A ranging from amino acids 50 to 132. In certain embodiments, the bispecific antibody binds to a peptide comprising the VEGF-C heparin domain of VEGF-A. In certain embodiments, the VEGF_C heparin domain of VEGF_A comprises a fragment of VEGF-A ranging from amino acids 143 to 191. In certain embodiments, the bispecific antibody binds to VEGF-A or a fragment thereof, hi certain embodiments, the bispecific antibody binds to VEGF_A or a fragment thereof with an EC50 of about 60 picomolar or less.In certain embodiments, the bispecific antibody inhibits the interaction of VEGF-A, or a fragment thereof, with a VEGF receptor. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF_A, or a fragment thereof, with a VEGF receptor with an IC50 of about 2000 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF_A, or a fragment thereof, with a VEGF receptor at least three times more potently than faricimab inhibits the interaction. In certain embodiments, the VEGF receptor is VEGF receptor 2 / kinase insert domain receptor (KDR). In certain embodiments, the ANG-2 binding moiety comprises a heavy chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the bispecific antibody comprises a common light chain. In certain embodiments, the common light chain is a surrogate light chain. In certain embodiments, the surrogate light chain comprises (a) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS), (b) a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK), and (c) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH). In certain embodiments, the surrogate light chain comprises a light chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the surrogate light chain comprises a light chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 22.In certain embodiments, the bispecific antibody comprises (a) a first heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 1; (b) a second heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 11; and (c) a common light chain variable region comprising a light chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 21, and binds to VEGF and ANG-2. In certain embodiments, the bispecific antibody binds to ANG-2. In certain embodiments, the bispecific antibody binds to ANG-2 with an EC50 of about 55 picomolar or less. In certain embodiments, the bispecific antibody binds to ANG-2 at least 50-fold more strongly than faricimab. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor with an IC50 of about 800 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at least 15-fold more strongly than faricimab. In certain embodiments, the ANG-2 receptor is a tyrosine kinase having immunoglobulin-like and EGF-like domain 2 receptor (Tie-2 receptor). In certain embodiments, the bispecific antibody or antigen-binding fragment thereof is human, chimeric, or humanized. In certain embodiments, the bispecific antibody or antigen-binding fragment thereof is humanized. Pharmaceutical compositions comprising the bispecific antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, excipient, or diluent are also described. In certain embodiments, the pharmaceutical composition is formulated for intravenous administration. In certain embodiments, the pharmaceutical composition is formulated for intravitreal administration. Nucleic acids encoding bispecific antibodies are also described herein. In certain embodiments, the nucleic acid is an expression vector.In certain embodiments, the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector. In certain embodiments, the expression vector is formulated for intravenous administration. In certain embodiments, the expression vector is formulated for intravitreal administration. Cells comprising a nucleic acid or an expression vector are also described herein. In certain embodiments, the cell is a eukaryotic cell suitable for producing a bispecific antibody. In certain embodiments, the bispecific antibody is used in a method for treating an ocular disease in an individual, the method comprising administering to the individual a bispecific antibody, a nucleic acid or nucleic acids encoding the bispecific antibody, or a pharmaceutical composition comprising the bispecific antibody, thereby treating the ocular disease. In certain embodiments, the ocular disease is macular degeneration. In certain embodiments, the macular degeneration is age-related. In certain embodiments, the macular degeneration is diabetes-related. In certain embodiments, the macular degeneration is wet macular degeneration. In certain embodiments, the ocular disease is branch retinal vein occlusion. In certain embodiments, the eye disease is central retinal vein occlusion.

[0007] In another aspect, described herein is a bispecific antibody that binds to VEGF and ANG-2, comprising: (a) a first heavy chain comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 2, (b) a second heavy chain comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 12, and (c) a common light chain, wherein the light chain comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the bispecific antibody binds to VEGF with an EC50 of about 60 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF_A, or a fragment thereof, with a VEGF receptor with an IC50 of about 2000 picomolar or less. In certain embodiments, the bispecific antibody binds to ANG-2 at least 50-fold more strongly than faricimab. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor with an IC50 of about 800 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at least 15-fold more strongly than faricimab. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF_A, or a fragment thereof, with a VEGF receptor at least 3-fold more strongly than faricimab inhibits the interaction. In certain embodiments, the bispecific antibody binds to ANG-2 with an EC50 of about 55 picomolar or less. In certain embodiments, the bispecific antibody or antigen-binding fragment thereof is human, chimeric, or humanized. In certain embodiments, the bispecific antibody or antigen-binding fragment thereof is humanized. Pharmaceutical compositions comprising the bispecific antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, excipient, or diluent are also described. In certain embodiments, the pharmaceutical composition is formulated for intravenous administration.In certain embodiments, the pharmaceutical composition is formulated for intravitreal administration. Nucleic acids encoding bispecific antibodies are also described herein. In certain embodiments, the nucleic acid is an expression vector. In certain embodiments, the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector. In certain embodiments, the expression vector is formulated for intravenous administration. In certain embodiments, the expression vector is formulated for intravitreal administration. Cells comprising the nucleic acid or expression vector are also described herein. In certain embodiments, the cell is a eukaryotic cell suitable for producing the bispecific antibody. In certain embodiments, the bispecific antibody is used in a method for treating an ocular disease in an individual, the method comprising administering to the individual a bispecific antibody, a nucleic acid or nucleic acids encoding the bispecific antibody, or a pharmaceutical composition comprising the bispecific antibody, thereby treating the ocular disease. In certain embodiments, the ocular disease is macular degeneration. In certain embodiments, the macular degeneration is age-related. In certain embodiments, the macular degeneration is diabetes-related. In certain embodiments, the macular degeneration is wet macular degeneration. In certain embodiments, the eye disease is branch retinal vein occlusion. In certain embodiments, the eye disease is central retinal vein occlusion.

[0008] In another aspect, described herein is a bispecific antibody comprising (a) a first heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain, the common light chain comprising the light chain set forth in SEQ ID NO:22, and which binds to VEGF and ANG-2. In certain embodiments, the bispecific antibody binds to VEGF with an EC50 of about 60 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF-A, or a fragment thereof, with a VEGF receptor. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF_A, or a fragment thereof, with a VEGF receptor with an IC50 of about 2000 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of VEGF_A, or a fragment thereof, with a VEGF receptor at least three-fold more potently than faricimab inhibits said interaction. In certain embodiments, the bispecific antibody binds to ANG-2 with an EC50 of about 55 picomolar or less. In certain embodiments, the bispecific antibody binds to ANG-2 at least 50-fold more strongly than faricimab. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor with an IC50 of about 800 picomolar or less. In certain embodiments, the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at least 15-fold more strongly than faricimab. In certain embodiments, the bispecific antibody or antigen-binding fragment thereof is human, chimeric, or humanized. In certain embodiments, the bispecific antibody or antigen-binding fragment thereof is humanized. Pharmaceutical compositions comprising the bispecific antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, excipient, or diluent are also described. In certain embodiments, the pharmaceutical composition is formulated for intravenous administration. In certain embodiments, the pharmaceutical composition is formulated for intravitreal administration. Nucleic acids encoding the bispecific antibody are also described herein. In certain embodiments, the nucleic acid is an expression vector.In certain embodiments, the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector. In certain embodiments, the expression vector is formulated for intravenous administration. In certain embodiments, the expression vector is formulated for intravitreal administration. Cells comprising a nucleic acid or an expression vector are also described herein. In certain embodiments, the cell is a eukaryotic cell suitable for producing a bispecific antibody. In certain embodiments, the bispecific antibody is used in a method for treating an ocular disease in an individual, the method comprising administering to the individual a bispecific antibody, a nucleic acid or nucleic acids encoding the bispecific antibody, or a pharmaceutical composition comprising the bispecific antibody, thereby treating the ocular disease. In certain embodiments, the ocular disease is macular degeneration. In certain embodiments, the macular degeneration is age-related. In certain embodiments, the macular degeneration is diabetes-related. In certain embodiments, the macular degeneration is wet macular degeneration. In certain embodiments, the ocular disease is branch retinal vein occlusion. In certain embodiments, the eye disease is central retinal vein occlusion. [Brief explanation of the drawings]

[0009] The novel features described herein are set forth with particularity in the appended claims. A better understanding of the features described herein and the advantages thereof will be obtained by reference to the following detailed description that sets forth illustrative examples in which the principles of the features described herein are utilized and the accompanying drawings in which: [Figure 1A]Figures 1A-1B show SDS-PAGE and SE-HPLC analyses of bispecific surrobodies produced in CHO cells and having amino acid sequences corresponding to SEQ ID NO:2, SEQ ID NO:12, and SEQ ID NO:22. Figure 1A shows the SDS-PAGE results for reduced and non-reduced samples. Lane 1, MW ladder; Lane 2, IgG control (non-reduced); Lane 3, Sample 1 (non-reduced); Lane 4, Sample 2 (non-reduced); Lane 5, Sample 3 (non-reduced); Lane 6, IgG control (reduced); Lane 7, Sample 1 (reduced); Lane 8, Sample 2 (reduced); Lane 5, Sample 3 (reduced). Figure 1B shows the SE-HPLC results for the three samples. [Figure 1B] Figures 1A-1B show SDS-PAGE and SE-HPLC analyses of bispecific surrobodies produced in CHO cells and having amino acid sequences corresponding to SEQ ID NO:2, SEQ ID NO:12, and SEQ ID NO:22. Figure 1A shows the SDS-PAGE results for reduced and non-reduced samples. Lane 1, MW ladder; Lane 2, IgG control (non-reduced); Lane 3, Sample 1 (non-reduced); Lane 4, Sample 2 (non-reduced); Lane 5, Sample 3 (non-reduced); Lane 6, IgG control (reduced); Lane 7, Sample 1 (reduced); Lane 8, Sample 2 (reduced); Lane 5, Sample 3 (reduced). Figure 1B shows the SE-HPLC results for the three samples. [Figure 2A]Figures 2A-2F show the binding of surrobody RO-101 to VEGF and its inhibition of the interaction between VEGF and its receptor, compared to faricimab. Figure 2A shows a sequence alignment between VEGF121 and VEGF165. Figure 2B shows ELISA binding results for RO-101 binding to VEGF121 or VEGF165. Figure 2C shows ELISA binding results for RO-101 or faricimab binding to VEGF121. Figure 2D shows ELISA binding results for RO-101 or faricimab binding to VEGF165. Figure 2E shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between VEGF and its receptor. Figure 2F shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between VEGF165 and its receptor. [Figure 2B] Figures 2A-2F show the binding of surrobody RO-101 to VEGF and its inhibition of the interaction between VEGF and its receptor, compared to faricimab. Figure 2A shows a sequence alignment between VEGF121 and VEGF165. Figure 2B shows ELISA binding results for RO-101 binding to VEGF121 or VEGF165. Figure 2C shows ELISA binding results for RO-101 or faricimab binding to VEGF121. Figure 2D shows ELISA binding results for RO-101 or faricimab binding to VEGF165. Figure 2E shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between VEGF and its receptor. Figure 2F shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between VEGF165 and its receptor. [Figure 2C]Figures 2A-2F show the binding of surrobody RO-101 to VEGF and its inhibition of the interaction between VEGF and its receptor, compared to faricimab. Figure 2A shows a sequence alignment between VEGF121 and VEGF165. Figure 2B shows ELISA binding results for RO-101 binding to VEGF121 or VEGF165. Figure 2C shows ELISA binding results for RO-101 or faricimab binding to VEGF121. Figure 2D shows ELISA binding results for RO-101 or faricimab binding to VEGF165. Figure 2E shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between VEGF and its receptor. Figure 2F shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between VEGF165 and its receptor. [Figure 2D] Figures 2A-2F show the binding of surrobody RO-101 to VEGF and its inhibition of the interaction between VEGF and its receptor, compared to faricimab. Figure 2A shows a sequence alignment between VEGF121 and VEGF165. Figure 2B shows ELISA binding results for RO-101 binding to VEGF121 or VEGF165. Figure 2C shows ELISA binding results for RO-101 or faricimab binding to VEGF121. Figure 2D shows ELISA binding results for RO-101 or faricimab binding to VEGF165. Figure 2E shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between VEGF and its receptor. Figure 2F shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between VEGF165 and its receptor. [Figure 2E]Figures 2A-2F show the binding of surrobody RO-101 to VEGF and its inhibition of the interaction between VEGF and its receptor, compared to faricimab. Figure 2A shows a sequence alignment between VEGF121 and VEGF165. Figure 2B shows ELISA binding results for RO-101 binding to VEGF121 or VEGF165. Figure 2C shows ELISA binding results for RO-101 or faricimab binding to VEGF121. Figure 2D shows ELISA binding results for RO-101 or faricimab binding to VEGF165. Figure 2E shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between VEGF and its receptor. Figure 2F shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between VEGF165 and its receptor. [Figure 2F] Figures 2A-2F show the binding of surrobody RO-101 to VEGF and its inhibition of the interaction between VEGF and its receptor, compared to faricimab. Figure 2A shows a sequence alignment between VEGF121 and VEGF165. Figure 2B shows ELISA binding results for RO-101 binding to VEGF121 or VEGF165. Figure 2C shows ELISA binding results for RO-101 or faricimab binding to VEGF121. Figure 2D shows ELISA binding results for RO-101 or faricimab binding to VEGF165. Figure 2E shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between VEGF and its receptor. Figure 2F shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between VEGF165 and its receptor. [Figure 3A]Figures 3A-3C show the binding of surrobody RO-101 to ANG-2 and its inhibition of the interaction between ANG-2 and its receptor compared to faricimab. Figure 3A shows ELISA binding results for the binding of RO-101 or faricimab to ANG-2. Figure 3B shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between ANG-2 and its receptor. Figure 3C shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between ANG-2 and its receptor. [Figure 3B] Figures 3A-3C show the binding of surrobody RO-101 to ANG-2 and its inhibition of the interaction between ANG-2 and its receptor compared to faricimab. Figure 3A shows ELISA binding results for the binding of RO-101 or faricimab to ANG-2. Figure 3B shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between ANG-2 and its receptor. Figure 3C shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between ANG-2 and its receptor. [Figure 3C] Figures 3A-3C show the binding of surrobody RO-101 to ANG-2 and its inhibition of the interaction between ANG-2 and its receptor compared to faricimab. Figure 3A shows ELISA binding results for the binding of RO-101 or faricimab to ANG-2. Figure 3B shows a diagram of an assay testing the ability of surrobodies to inhibit the interaction between ANG-2 and its receptor. Figure 3C shows ELISA binding results for RO-101 or faricimab inhibition of the interaction between ANG-2 and its receptor. [Figure 4A] Figures 4A-4B show different forms of RO-101 binding to VEGF and ANG-2. Figure 4A shows ELISA binding results for the binding between RO-101SgG, scSv, or Sab derived from RO-101 and VEGF. Figure 4B shows ELISA binding results for the binding between RO-101SgG, scSv, or Sab derived from RO-101 and ANG-2. [Figure 4B]Figures 4A-4B show different forms of RO-101 binding to VEGF and ANG-2. Figure 4A shows ELISA binding results for the binding between RO-101SgG, scSv, or Sab derived from RO-101 and VEGF. Figure 4B shows ELISA binding results for the binding between RO-101SgG, scSv, or Sab derived from RO-101 and ANG-2. [Figure 5A] Figures 5A-5D show the binding of RO-101 to other PDGF / VEGF family members. Figure 5A shows the sequence alignment between VEGF_B, VEGF_C, VEGF_D, PIGF-1, and PIGF-3. Figure 5B shows ELISA binding results for RO-101 binding to VEGF_B from different suppliers compared to VEGF165. Figure 5C shows the binding of RO-101 to VEGF_C or VEGF_D compared to VEGF165. Figure 5D shows the binding of RO-101 to PIGF-1 or PIGF-3 compared to VEGF165. [Figure 5B] Figures 5A-5D show the binding of RO-101 to other PDGF / VEGF family members. Figure 5A shows the sequence alignment between VEGF_B, VEGF_C, VEGF_D, PIGF-1, and PIGF-3. Figure 5B shows ELISA binding results for RO-101 binding to VEGF_B from different suppliers compared to VEGF165. Figure 5C shows the binding of RO-101 to VEGF_C or VEGF_D compared to VEGF165. Figure 5D shows the binding of RO-101 to PIGF-1 or PIGF-3 compared to VEGF165. [Figure 5C]Figures 5A-5D show the binding of RO-101 to other PDGF / VEGF family members. Figure 5A shows the sequence alignment between VEGF_B, VEGF_C, VEGF_D, PIGF-1, and PIGF-3. Figure 5B shows ELISA binding results for RO-101 binding to VEGF_B from different suppliers compared to VEGF165. Figure 5C shows the binding of RO-101 to VEGF_C or VEGF_D compared to VEGF165. Figure 5D shows the binding of RO-101 to PIGF-1 or PIGF-3 compared to VEGF165. [Figure 5D] Figures 5A-5D show the binding of RO-101 to other PDGF / VEGF family members. Figure 5A shows the sequence alignment between VEGF_B, VEGF_C, VEGF_D, PIGF-1, and PIGF-3. Figure 5B shows ELISA binding results for RO-101 binding to VEGF_B from different suppliers compared to VEGF165. Figure 5C shows the binding of RO-101 to VEGF_C or VEGF_D compared to VEGF165. Figure 5D shows the binding of RO-101 to PIGF-1 or PIGF-3 compared to VEGF165. [Figure 6A] Figures 6A-6D show the binding of RO-101 to non-human orthologs of VEGF or ANG-2. Figure 6A shows a sequence alignment between VEGF orthologs from human, rabbit, dog, and pig. Figure 6B shows ELISA binding results for RO-101 binding to VEGF orthologs from human, rabbit, dog, and pig. Figure 6C shows a sequence alignment between ANG-2 orthologs from human, rabbit, dog, and pig. Figure 6D shows ELISA binding results for RO-101 binding to ANG-2 orthologs from human, rabbit, and dog. [Figure 6B]Figures 6A-6D show the binding of RO-101 to non-human orthologs of VEGF or ANG-2. Figure 6A shows a sequence alignment between VEGF orthologs from human, rabbit, dog, and pig. Figure 6B shows ELISA binding results for RO-101 binding to VEGF orthologs from human, rabbit, dog, and pig. Figure 6C shows a sequence alignment between ANG-2 orthologs from human, rabbit, dog, and pig. Figure 6D shows ELISA binding results for RO-101 binding to ANG-2 orthologs from human, rabbit, and dog. [Figure 6C] Figures 6A-6D show the binding of RO-101 to non-human orthologs of VEGF or ANG-2. Figure 6A shows a sequence alignment between VEGF orthologs from human, rabbit, dog, and pig. Figure 6B shows ELISA binding results for RO-101 binding to VEGF orthologs from human, rabbit, dog, and pig. Figure 6C shows a sequence alignment between ANG-2 orthologs from human, rabbit, dog, and pig. Figure 6D shows ELISA binding results for RO-101 binding to ANG-2 orthologs from human, rabbit, and dog. [Figure 6D] Figures 6A-6D show the binding of RO-101 to non-human orthologs of VEGF or ANG-2. Figure 6A shows a sequence alignment between VEGF orthologs from human, rabbit, dog, and pig. Figure 6B shows ELISA binding results for RO-101 binding to VEGF orthologs from human, rabbit, dog, and pig. Figure 6C shows a sequence alignment between ANG-2 orthologs from human, rabbit, dog, and pig. Figure 6D shows ELISA binding results for RO-101 binding to ANG-2 orthologs from human, rabbit, and dog. DETAILED DESCRIPTION OF THE INVENTION

[0010] In one aspect, described herein is a vascular endothelial growth factor (VEGF) binding antibody or antigen-binding fragment thereof, comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO:3 (GYTFSIYT), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO:4 (INPYNGNT), and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO:5 (AKAPAVFWWTGLDY), wherein the antibody binds to VEGF.

[0011] In another aspect, described herein is an angiopoietin-2 (ANG-2) binding antibody or antigen-binding fragment thereof, comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY), wherein the antibody binds to ANG-2.

[0012] In another aspect, a bispecific antibody is provided, comprising a vascular endothelial growth factor (VEGF) binding portion, the VEGF binding portion comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT), and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY), and angiopoietin 2 (ANG)-1 (ANGI ...

[0010] Described herein is a bispecific antibody that binds to VEGF and ANG-2, comprising an angiopoietin 2 (ANG-2) binding portion, the bispecific antibody comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY).

[0013]

[0013] In another aspect, described herein is a bispecific antibody that binds to VEGF and ANG-2, comprising: (a) a first heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 1; (b) a second heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 11; and (c) a common light chain variable region, wherein the light chain variable region comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 21.

[0014]

[0013] In another aspect, described herein is a bispecific antibody, wherein the bispecific antibody comprises: (a) a first heavy chain comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 2; (b) a second heavy chain comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 12; and (c) a common light chain, wherein the light chain comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 22; and wherein the bispecific antibody binds to VEGF and ANG-2.

[0015] In another aspect, described herein is a bispecific antibody comprising: (a) a first heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 2; (b) a second heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 12; and (c) a common light chain, wherein the common light chain comprises the light chain set forth in SEQ ID NO: 22; and wherein the bispecific antibody binds to VEGF and ANG-2.

[0016] In the following description, certain specific details are set forth to provide a thorough understanding of various embodiments. However, those skilled in the art will understand that the provided embodiments may be practiced without these details. Unless the context otherwise requires, throughout the following specification and claims, the term "comprise" and variations thereof (such as "comprises" and "comprising") should be construed in an inclusive sense, i.e., "including but not limited to." As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally used in its sense including "and / or" unless the content clearly dictates otherwise. Moreover, the headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.

[0017] As used herein, the term "about" refers to an amount closer to the stated amount by no more than 10%.

[0018] As used herein, "vascular endothelial growth factor" or "VEGF" refers to the polypeptide encoded by the VEGFA gene, whose amino acid sequence is available at www.uniprot.org / uniprot / P15692. Such sequences include post-translational modifications, naturally occurring amino acid variants, and naturally occurring splice variants that do not affect binding of the antibodies and bispecific antibodies described herein.

[0019] As used herein, "angiopoietin 2" or "ANG-2" refers to the polypeptide encoded by the ANGPT2 gene, whose amino acid sequence is available at www.uniprot.org / uniprot / O15123. Such sequences include post-translational modifications, naturally occurring amino acid variants, and naturally occurring splice variants that do not affect binding of the antibodies and bispecific antibodies described herein.

[0020] As used herein, "surrogate light chain" refers to a light chain formed by the fusion of a VpreB polypeptide with a λ5 polypeptide, which can be indiscriminately linked to two or more structurally distinct heavy chains. Such surrogate light chains are described in U.S. Pat. Nos. 8,114,967, 10,214,580, and 8,969,082, each of which is incorporated herein by reference in its entirety.

[0021] As used herein, the terms "individual," "patient," or "subject" refer to an individual diagnosed with, suspected of suffering from, or at risk of developing at least one disease that the described compositions and methods are useful for treating. In certain embodiments, the individual is a mammal. In certain embodiments, the mammal is a mouse, rat, rabbit, dog, cat, horse, cow, sheep, pig, goat, llama, alpaca, or yak. In certain embodiments, the individual is a human.

[0022] The antibodies provided include monoclonal antibodies, multispecific antibodies (e.g., bispecific and polyreactive antibodies), and antibody fragments. Antibodies include antibody-containing molecules such as antibody-conjugates and chimeric molecules. Thus, antibodies include, but are not limited to, full-length, naturally occurring antibodies, fragments and portions thereof that retain their binding specificity, such as any specific binding portion thereof, including those of any number of immunoglobulin classes and / or isotypes (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, IgE, and IgM), as well as biologically relevant (antigen-binding) fragments or specific binding portions thereof, including, but not limited to, Fab, F(ab'), Fv, and scFv (single-chain or related entities). Monoclonal antibodies are generally within a substantially homogeneous antibody composition; therefore, any individual antibodies contained within a monoclonal antibody composition are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies may include a human IgG1 constant region. The monoclonal antibody can include a human IgG4 constant region.

[0023] The term "antibody" as used herein is used in the broadest sense and includes monoclonal antibodies, bispecific antibodies, and includes intact antibodies and functional (antigen-binding) antibody fragments thereof, including antigen-binding (Fab) fragments; F(ab') fragments; Fab' fragments; Fv fragments; recombinant IgG (rIgG) fragments; single-chain antibody fragments, including single-chain variable fragments (sFv or scFv); and single-domain antibody (e.g., sdAb, sdFv, nanobody) fragments. The term also encompasses genetically engineered and / or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific antibodies, e.g., bispecific antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFv, tandem tri-scFv, etc. Unless otherwise specified, the term "antibody" should be understood to include functional antibody fragments thereof. The term also encompasses intact or full-length antibodies, including antibodies of any class or subclass, including IgG and its subclasses, IgM, IgE, IgA, and IgD. The antibody can comprise a human IgG1 constant region. The antibody can comprise a human IgG4 constant region.

[0024] As used herein, a molecule, peptide, polypeptide, antibody, or antibody fragment may be referred to as "bispecific" or "dual-specific," including grammatical equivalents. Bispecific molecules have the ability to specifically bind to at least two structurally distinct targets. Specific binding can occur between two distinct binding moieties that are structurally distinct at the molecular level, including, but not limited to, different, non-identical amino acid sequences, or with high affinity (e.g., about 1×10 -6This can be the result of a single binding moiety that can specifically bind to two structurally distinct targets (with a KD of less than 0.01). A molecule, peptide, polypeptide, antibody, or antibody fragment referred to as "multispecific" refers to a molecule that has the ability to specifically bind to at least three structurally distinct targets. A "bispecific antibody," including grammatical equivalents, refers to a bispecific molecule that preserves at least one fragment of an antibody, e.g., a variable region, heavy or light chain, or one or more complementarity-determining regions, from an antibody molecule, that can specifically bind to a target. A "multispecific antibody," including grammatical equivalents, refers to a multispecific molecule that preserves at least one fragment of an antibody, e.g., a variable region, heavy or light chain, or one or more complementarity-determining regions, from an antibody molecule, that can specifically bind to a target.

[0025] The terms "complementarity-determining region" and "CDR," which are synonymous with "hypervariable region" or "HVR," are known in the art to refer to non-contiguous sequences of amino acids in an antibody variable region that confer antigen specificity and / or binding affinity. Generally, there are three CDRs (CDR-H1, CDR-H2, CDR-H3) in each heavy chain variable region, and three CDRs (CDR-L1, CDR-L2, CDR-L3) in each light chain variable region. The terms "framework region" and "FR" are known in the art to refer to the non-CDR portions of the heavy and light chain variable regions. Generally, there are four FRs (FR-H1, FR-H2, FR-H3, and FR-H4) in each full-length heavy chain variable region, and four FRs (FR-L1, FR-L2, FR-L3, and FR-L4) in each full-length light chain variable region.The precise amino acid sequence boundaries of a given CDR or FR can be determined using the following numbering schemes: Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme); Al-Lazikani et al. (1997) JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262, 732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography," J. Mol. Biol. 262, 732-745 ("Contact" numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol. 2003 Jan;27(1):55-77 ("IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol, 2001 Jun 8;309(3):657-70, ("Aho" numbering scheme); and Whitelegg NR and Rees AR, "WAM: an improved algorithm for modeling antibodies on the WEB," Protein Eng. 2000 Dec;13(12):819-24 ("AbM" numbering scheme).In certain embodiments, the CDRs of the antibodies described herein can be defined in a manner selected from Kabat, Chothia, IMGT, Aho, AbM, or a combination thereof.

[0026] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignment, while the Chothia scheme is based on structural information. Both the Kabat and Chothia numbering schemes are based on the most common antibody region sequence lengths, with insertions accommodated by insertion letters, such as "30a," and deletions occurring in some antibodies. The two schemes place specific insertions and deletions ("indels") at different positions, resulting in differential numbering. The contact scheme is based on the analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.

[0027] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains (V, respectively) of a native antibody H and V L ) have a generally similar structure, with each domain containing four conserved framework regions (FR) and three CDRs (see, for example, Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007)). H or V L The V domain may be sufficient to confer antigen-binding specificity. Furthermore, an antibody that binds to a particular antigen may have a V domain derived from the antibody that binds to the antigen. H or V L domains and complementary V L or V H Libraries of domains can be screened individually (see, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991)).

[0028] The specific binding or binding of antibody molecules described herein refers to the binding mediated by one or more CDR portions of antibody.Not all CDRs are required for specific binding.Specific binding can be demonstrated, for example, by ELISA against a specific listed target or antigen, which shows significant increase in binding compared with isotype control antibody.

[0029] As used herein, "epitope" refers to the binding determinant of an antibody or fragment described herein that is minimally required for specific binding of the antibody or fragment to the target antigen. When the target antigen is a polypeptide, the epitope may be a continuous or discontinuous epitope. A continuous epitope is formed by a single region of the target antigen, while a discontinuous epitope may be formed from two or more distinct regions. A discontinuous epitope may be formed, for example, when the target antigen adopts a tertiary structure in which two amino acid sequences are combined to form a three-dimensional structure to which an antibody binds. When the target antigen is a polypeptide, the epitope is typically multiple amino acids linked to the polypeptide chain. A continuous epitope may include 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive amino acids. An epitope may include a continuous polymer of amino acids, but not all amino acids in the polymer may contact an amino acid residue of an antibody. Such non-contact amino acids may be important for the structure and linkage of the contact amino acids, and therefore still comprise part of the epitope. Those skilled in the art can determine whether any given antibody binds to the epitope of a reference antibody, for example, by cross-blocking experiments using a reference antibody. In certain embodiments, described herein are antibodies that bind to the same epitope as the described antibody. In certain embodiments, described herein are antibodies that are competitively blocked by the described antibody. In certain embodiments, described herein are antibodies that compete for binding with the described antibody.

[0030] The provided antibodies include antibody fragments. An "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv or sFv); and multispecific antibodies formed from antibody fragments. In certain embodiments, the antibody is a single-chain antibody fragment containing the variable heavy chain region and / or the variable light chain region, such as scFv.

[0031] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells. In some embodiments, the antibody is a recombinantly produced fragment, e.g., a fragment containing a non-naturally occurring sequence, e.g., one having two or more antibody regions or chains linked by a synthetic linker, e.g., a polypeptide linker, and / or one that is not produced by enzymatic digestion of a naturally occurring intact antibody. In some aspects, the antibody fragment is an scFv.

[0032] A "humanized" antibody is an antibody in which all or substantially all CDR amino acid residues are derived from non-human CDRs and all or substantially all FR amino acid residues are derived from human FRs. A humanized antibody may optionally contain at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of a non-human antibody refers to a variant of a non-human antibody that has undergone humanization, typically to reduce immunogenicity to humans, while retaining the specificity and affinity of the parent non-human antibody. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0033] The provided antibodies include human antibodies. A "human antibody" is an antibody having an amino acid sequence corresponding to that of an antibody produced by a human or human cell, or a non-human source, using a human antibody repertoire or other human antibody-encoding sequence, including a human antibody library. This term excludes humanized forms of non-human antibodies containing non-human antigen-binding regions, such as those in which all or substantially all CDRs are non-human.

[0034] Human antibodies can be prepared by administering immunogens to transgenic animals that have been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigen challenge. Such animals typically contain all or part of a human immunoglobulin locus that replaces the endogenous immunoglobulin locus, or that is present extrachromosomally or randomly inserted into the animal's chromosome. In such transgenic animals, the endogenous immunoglobulin locus is generally inactivated. Human antibodies can also be derived from human antibody libraries, including phage display and cell-free libraries, that contain antibody coding sequences derived from the human repertoire.

[0035] The terms "polypeptide" and "protein" are used interchangeably to refer to polymers of amino acid residues and are not limited to a minimum length. Polypeptides, including the provided antibodies and antibody chains and other peptides, e.g., linkers and connecting peptides, can contain amino acid residues, including natural and / or unnatural amino acid residues. The term also includes post-expression modifications of the polypeptide, e.g., glycosylation, sialylation, acetylation, phosphorylation, etc. In some aspects, a polypeptide can contain modifications to its native or natural sequence, so long as the protein maintains the desired activity. These modifications can be deliberate, such as by site-directed mutagenesis, or can be accidental, such as by mutations of hosts producing the protein or by errors due to PCR amplification. In some embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. Variants typically differ from the polypeptides specifically disclosed herein in one or more substitutions, deletions, additions, and / or insertions. Such variants may be naturally occurring or may be synthetically produced, for example, by modifying one or more of the above polypeptide sequences of the present invention and evaluating one or more biological activities of the polypeptides described herein, and / or using any of several known techniques. For example, amino acid sequence variants of antibodies can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletion and / or insertion and / or substitution of residues within the amino acid sequence of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct has the desired characteristics, for example, antigen binding.

[0036] The percent (%) sequence identity to a reference polypeptide sequence is the percent of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of known ways, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences can be determined, including the algorithm required to achieve maximum alignment across the entire length of the sequences being compared. However, for the purposes of this specification, the percent amino acid sequence identity value is generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and its source code has been submitted, along with user documentation, to the U.S. Copyright Office, Washington, DC 20559, and is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0037] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, with, or relative to a given amino acid sequence B (alternatively, this may be referred to as a given amino acid sequence A having or comprising a particular % amino acid sequence identity to, with, or relative to a given amino acid sequence B) is calculated as the fraction X / Y x 100, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and Y is the total number of amino acid residues in B. If the length of amino acid sequence A is not equal to the length of amino acid sequence B, then the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program, as described in the immediately preceding paragraph.

[0038] Amino acid sequence insertions and deletions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions and deletions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody with an N-terminal methionyl residue. Other insertional variants of antibody molecules include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or polypeptide that increases the serum half-life of the antibody. An example of an intrasequence insertional variant of an antibody molecule includes an insertion of three amino acids in the light chain. An example of a terminal deletion includes an antibody with a deletion of seven or fewer amino acids at the end of the light chain.

[0039] In some embodiments, the antibodies provided herein have an activity against the antibody target of about 1 μM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM or less (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13M, e.g., 10 -9 M~10 -13 In some embodiments, the antibodies provided herein have a dissociation constant (KD) for the antibody target of about 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.001 nM or greater (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13 M). The antibody target may be an anti-VEGF or anti-ANG-2 antibody. KD can be measured by any suitable assay. In certain embodiments, KD can be measured using a surface plasmon resonance assay (e.g., BIACORE®-2000, -3000, or Octet BIACORE®).

[0040] VEGF-A may have several different splice sites and therefore may have various isoforms depending on the splice site. Thus, in certain embodiments, the antibodies disclosed herein may bind to VEGF-A. 165 In certain embodiments, the antibodies disclosed herein bind to VEGF. 121 In certain embodiments, VEGF 121The binding affinity of an antibody to VEGF_A is predictive of the antibody's effectiveness in treating ocular diseases. In certain embodiments, the antibodies disclosed herein bind to a peptide comprising the platelet-derived growth factor (PDGF) domain of VEGF_A. In some embodiments, the PDGF domain of VEGF_A comprises a fragment of VEGF_A ranging from about amino acid 40, 41, 42, 43, 44, 45, 46, 46, 47, 48, 49, or 50 to about amino acid 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, or 140. In certain embodiments, the antibodies disclosed herein bind to a peptide comprising the VEGF_C heparin domain of VEGF_A. In some embodiments, the VEGF_C heparin domain of VEGF_A comprises a fragment of VEGF_A ranging from about amino acid 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 to about amino acid 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 120. In certain embodiments, the antibodies disclosed herein bind to VEGF_A from human or non-human species (e.g., rabbit, canines (dogs), or porcine (pigs)).

[0041] In certain embodiments, the antibody has a K of 100, 75, 60, 50, 40, 30, or 25 picomolar or less. D or EC 50 In certain embodiments, the antibody is an anti-human VEGF antibody that binds to human VEGF with a K of 100, 75, 60, 50, 40, 30, or 25 picomolar or less. D or EC 50 In certain embodiments, the antibody is an anti-human VEGF_A antibody that binds to human VEGF with a K of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 picomolar or greater. D or EC 50 In certain embodiments, the antibodies disclosed herein are anti-human VEGF_A antibodies that bind to human VEGF at an EC ratio between faricimab and VEGF_A or a fragment thereof. 50 Similar to EC 50In certain embodiments, the antibodies disclosed herein bind to VEGF_A or a fragment thereof with an EC2 that is lower than that between faricimab and VEGF_A or a fragment thereof. 50 , 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 pM and bind to VEGF_A or its fragments.

[0042] In certain embodiments, the antibody is an anti-human VEGFA antibody that inhibits the interaction of VEGF-A or a fragment thereof with a VEGF receptor. In certain embodiments, the antibody inhibits the interaction of VEGF-A or a fragment thereof with a VEGF receptor with an IC of 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 900 pM, 800 pM, 700 pM, 600 pM or less. 50 In certain embodiments, the antibody has an IC50 of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 picomolar or greater. 50 and anti-human VEGF-A antibodies that inhibit the interaction of VEGF-A or a fragment thereof with a VEGF receptor by at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold more potently than faricimab inhibits the interaction. In certain embodiments, the VEGF receptor is VEGF receptor 2 / kinase insert domain receptor (KDR).

[0043] In certain embodiments, the antibodies disclosed herein bind significantly less to VEGF_B than to VEGF_A. In certain embodiments, the antibodies disclosed herein bind significantly less to VEGF_C than to VEGF_A. In certain embodiments, the antibodies disclosed herein bind significantly less to VEGF_D than to VEGF_A. In certain embodiments, the antibodies disclosed herein bind significantly less to PIGF-1 than to VEGF_A. In certain embodiments, the antibodies disclosed herein bind significantly less to PIGF-3 than to VEGF_A.

[0044] In certain embodiments, the antibody has a K of 100, 75, 60, 55, 50, 40, 30, or 25 picomolar or less. D or EC 50 In certain embodiments, the antibody is an anti-human ANG-2 antibody that binds to human ANG-2 with a K of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 picomolar or greater. D or EC 50 In certain embodiments, the antibody binds to ANG-2 at least 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, or 70-fold more strongly than faricimab binds to ANG-2.

[0045] In certain embodiments, the antibody is an anti-human ANG-2 antibody that inhibits the interaction of ANG-2 with the ANG-2 receptor. In certain embodiments, the antibody has an IC of 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 900 pM, 800 pM, 700 pM, 600 pM or less. 50 In certain embodiments, the antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at an IC50 of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 picomolar or greater. 50 In some embodiments, the antibodies disclosed herein inhibit the interaction of ANG-2 with the ANG-2 receptor at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, or 15-fold more potently than faricimab. In some embodiments, the ANG-2 receptor is a tyrosine kinase with immunoglobulin-like and EGF-like domain 2 receptor (Tie-2 receptor).

[0046] In certain embodiments, the antibody has a K of 100, 75, 60, 50, 40, 30, or 25 picomolar or less. D or EC 50In certain embodiments, the antibody is an anti-human VEGF / ANG-2 bispecific antibody that binds to human VEGF with a K of 100, 75, 60, 50, 40, 30, or 25 picomolar or less. D or EC 50 In certain embodiments, the antibody is an anti-human VEGF / ANG-2 bispecific antibody that binds to human VEGF_A with a K of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 picomolar or greater. D or EC 50 It is an anti-human VEGF / ANG-2 bispecific antibody that binds to human VEGF_A.

[0047] In certain embodiments, the antibody has a K of 100, 75, 60, 50, 40, 30, or 25 picomolar or less. D or EC 50 In certain embodiments, the antibody is an anti-human VEGF / ANG-2 bispecific antibody that binds to human ANG-2 with a K of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 picomolar or greater. D or EC 50 It is an anti-human VEGF / ANG-2 bispecific antibody that binds to human ANG-2.

[0048] In some embodiments, the antibodies disclosed herein are IgG antibodies. In some embodiments, the antibodies disclosed herein are IgE antibodies. In some embodiments, the antibodies disclosed herein are IgM antibodies. In some embodiments, the antibodies disclosed herein are IgA antibodies. In some embodiments, the antibodies disclosed herein are Fab, F(ab)2, single domain antibodies, or single chain variable fragments (scFv).

[0049] In some embodiments, the antibodies disclosed herein that are paired with one or more surrogate light chains are surrobodies, hi some embodiments, the antigen-binding fragments thereof are surrobody antigen-binding fragments (Sab) or single-chain variable fragments of surrobodies (scSv).

[0050] In some embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region herein refers to the C-terminal region of an immunoglobulin heavy chain, including at least a portion of the constant region. Fc regions include native-sequence Fc regions and variant Fc regions. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) containing an amino acid modification (e.g., substitution) at one or more amino acid positions.

[0051] In some embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region herein refers to the C-terminal region of an immunoglobulin heavy chain, including at least a portion of the constant region. Fc regions include native-sequence Fc regions and variant Fc regions. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) containing an amino acid modification (e.g., substitution) at one or more amino acid positions.

[0052] In some examples, the Fc region of an immunoglobulin is important for many important antibody functions (e.g., effector functions), such as antigen-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP), which result in target cell killing, albeit through different mechanisms. Thus, in some embodiments, the antibodies described herein comprise a variable domain of the invention combined with a constant domain comprising a different Fc region, selected based on the biological activity of the antibody for its intended use. In a particular example, human IgG can be classified into, for example, four subclasses, IgG1, IgG2, IgG3, and IgG4, each of which comprises an Fc region with a unique profile for binding to one or more Fcγ receptors (activating receptors FcγRI (CD64), FcγRIIA, FcγRIIC (CD32); FcγRIIIA and FcγRIIIB (CD16) and inhibitory receptor FcγRIIB) and for the first component of complement (Clq). Human IgG1 and IgG3 bind to all Fcγ receptors; IgG2 binds to FcγRIIA H131 binds to FcγRIIA H131 FcγRIIIA V158 IgG4 binds with lower affinity to FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, and FcγRIIIA V158 Furthermore, the inhibitory receptor FcγRIIB has lower affinity for IgG1, IgG2, and IgG3 than all other Fcγ receptors. Studies have shown that FcγRI does not bind to IgG2, and FcγRIIIB does not bind to IgG2 or IgG4. Ibid. In general, with regard to ADCC activity, the order of human IgG1 > IgG3 > IgG4 > IgG2.

[0053] In some embodiments, antibodies of the present disclosure are variants with reduced effector function, making them desirable candidates for applications in which certain effector functions (such as complement fixation and ADCC) are unnecessary or deleterious. Such antibodies may have reduced complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), or antibody-dependent cellular phagocytosis (ADCP). In some embodiments, antibodies of the present disclosure are variants with increased effector function for applications in which increased immunogenicity is beneficial. Such antibodies may have increased CDC, ADCC, or ADCP, or a combination thereof. Non-limiting examples of in vitro assays for assessing ADCC activity of a molecule of interest are described in U.S. Patent Nos. 5,500,362 and 5,821,337. Alternatively, non-radioactive assays may be used (e.g., ACTI™ and CytoTox 96® non-radioactive cytotoxicity assays). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC), monocytes, macrophages, and natural killer (NK) cells.

[0054] The antibody may have an increased half-life and improved binding to the neonatal Fc receptor (FcRn) (see, e.g., US 2005 / 0014934). Such antibodies may comprise an Fc region with one or more substitutions that improve binding of the Fc region to FcRn, including those with substitutions at one or more of the following Fc region residues, according to the EU numbering system: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 (see, e.g., U.S. Patent No. 7,371,826). Other examples of Fc region variants are also contemplated (see, e.g., Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent Nos. 5,648,260 and 5,624,821; and WO 94 / 29351).

[0055] In some embodiments, it may be desirable to generate cysteine engineered antibodies, e.g., "thioMAbs," in which one or more residues of an antibody are substituted with a cysteine residue. In some embodiments, the substituted residue occurs at an accessible site of the antibody. The reactive thiol group may be positioned at a site for conjugation to another moiety (e.g., a drug moiety or a linker-drug moiety) to generate an immunoconjugate. In some embodiments, any one or more of the following residues may be substituted with a cysteine: V205 (Kabat numbering) of the light chain, A118 (EU numbering) of the heavy chain, and S400 (EU numbering) of the heavy chain Fc region.

[0056] In some embodiments, the antibodies provided herein may be further modified to contain additional known and available nonproteinaceous moieties. Suitable moieties for derivatizing antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone), polyethylene glycol, polypropylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. Polymers may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules.

[0057] The antibodies described herein can be encoded by nucleic acids. Nucleic acids are a type of polynucleotide containing two or more nucleotide bases. In certain embodiments, the nucleic acid is a component of a vector that can be used to introduce a polynucleotide encoding a polypeptide into a cell. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a genomic integrated vector or "integrated vector," which can be inserted into the chromosomal DNA of a host cell. Another type of vector is an "episomal" vector, e.g., a nucleic acid capable of extrachromosomal replication. Vectors capable of inducing the expression of an operably linked gene are referred to herein as "expression vectors." Suitable vectors include plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, viral vectors, and the like. In expression vectors, regulatory elements such as promoters, enhancers, and polyadenylation signals used to control transcription can be derived from mammalian, microbial, viral, or insect genes. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene for facilitating recognition of transformants can also be incorporated. Vectors derived from viruses such as lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses may also be used. Plasmid vectors can be linearized for insertion into genomic regions. In certain embodiments, the expression vector is a plasmid. In certain embodiments, the expression vector is a lentivirus, adenovirus, or adeno-associated virus. In certain embodiments, the expression vector is an adenovirus. In certain embodiments, the expression vector is an adeno-associated virus. In certain embodiments, the expression vector is a lentivirus. In certain embodiments, the expression vector described herein is used in gene therapy. Thus, in some embodiments, the expression vector described herein is formulated for intravenous administration. In some embodiments, the expression vector described herein is formulated for intravitreal administration.

[0058] As used herein, the terms "homologous," "homology," or "percent homology," when used herein to describe an amino acid sequence or a nucleic acid sequence relative to a reference sequence, can be determined using the formula described by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268, 1990, modified as in Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993). Such formula is incorporated into the Basic Local Alignment Search Tool (BLAST) program of Altschul et al. (J. Mol. Biol. 215:403-410, 1990). Percent sequence homology can be determined using the latest version of BLAST as of the filing date of this application.

[0059] Nucleic acids encoding the antibodies described herein can be used to infect, transfect, transform, or otherwise transgenic suitable cells, thus enabling the production of antibodies for commercial or therapeutic use. Standard cell lines and methods for the production of antibodies from large-scale cell culture are known in the art. See, for example, Li et al., "Cell culture processes for monoclonal antibody production." Mabs. 2010 Sep-Oct;2(5):466-477. In certain embodiments, the cell is a eukaryotic cell. In certain embodiments, the eukaryotic cell is a mammalian cell. In certain embodiments, the mammalian cell is a cell line useful for producing antibodies that is a Chinese hamster ovary (CHO) cell, an NS0 mouse myeloma cell, or a PER.C6® cell. In certain embodiments, the nucleic acid encoding the antibody is inserted into a genomic locus of a cell useful for producing the antibody. In certain embodiments, methods of making an antibody are described herein that include culturing in vitro cells containing nucleic acid encoding the antibody under conditions sufficient to allow the production and secretion of the antibody.

[0060] In certain embodiments, described herein is a master cell bank comprising (a) a mammalian cell line comprising a nucleic acid encoding an antibody or bispecific antibody described herein inserted at a genomic location, and (b) a cryoprotectant. In certain embodiments, the cryoprotectant comprises glycerol or DMSO. In certain embodiments, the master cell bank comprises (a) a CHO cell line comprising a nucleic acid encoding an antibody or bispecific antibody described herein inserted at a genomic location, and (b) a cryoprotectant. In certain embodiments, the cryoprotectant comprises glycerol or DMSO. In certain embodiments, the master cell bank is contained in a suitable vial or container that can withstand freezing with liquid nitrogen.

[0061] Also described herein are methods for producing the antibodies described herein. Such methods include incubating cells or cell lines containing nucleic acids encoding the antibodies in cell culture medium under conditions sufficient to allow expression and secretion of the antibodies, and further recovering the antibodies from the cell culture medium. Harvesting may further include one or more purification steps to remove viable cells, cell debris, non-antibody proteins or polypeptides, undesired salts, buffers, and medium components. In certain embodiments, additional purification steps include centrifugation, ultracentrifugation, Protein A, Protein G, Protein A / G, or Protein L purification, and / or ion exchange chromatography.

[0062] Treat," "treatment," or "treating," as used herein, refers to the deliberate intervention in a physiological disease state, such as resulting in a reduction in the severity of a disease or condition, shortening the duration of the course of the condition, ameliorating or eliminating one or more symptoms associated with a disease or condition, or providing a beneficial effect to a subject with a disease or condition. Treatment does not require curing the underlying disease or condition.

[0063] A "therapeutically effective amount," "effective dose," "effective amount," or "therapeutically effective dosage" of a drug or therapeutic agent is any amount of drug that, when used alone or in combination with another therapeutic agent, protects a subject from developing disease or promotes disease regression, as evidenced by a decrease in the severity of disease symptoms, an increase in the frequency and duration of disease-free periods, or prevention of impairment or disability due to the affliction of the disease. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to those skilled in the art, such as by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0064] As used herein, "pharmaceutically acceptable" with respect to "carrier," "excipient," or "diluent" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In some embodiments, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., antibody, can be coated in a material that protects the compound from the action of acids and other natural conditions that may inactivate the compound.

[0065] The pharmaceutical compounds described herein may contain one or more pharmaceutically acceptable salts. A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see, e.g., Berge, SM et al. (1977) J. Pharm. Sci. 66:1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from non-toxic inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, and phosphorous acid, as well as non-toxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, and aliphatic and aromatic sulfonic acids. Base addition salts include those derived from alkaline earth metals such as sodium, potassium, magnesium, and calcium, and non-toxic organic amines such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, and procaine.

[0066] VEGF antibody Described herein are antibodies that bind to a VEGF protein. In some embodiments, the VEGF protein is a human VEGF protein.

[0067] In certain embodiments, described herein is a vascular endothelial growth factor (VEGF)-binding antibody or antigen-binding fragment thereof, wherein the antibody comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT), and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY), wherein the antibody binds to VEGF.

[0068] In certain embodiments, described herein is a vascular endothelial growth factor (VEGF)-binding antibody or antigen-binding fragment thereof, comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT), a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY), a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS), a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK), and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH), wherein the antibody binds to VEGF.

[0069] In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the heavy chain variable region of the VEGF antibody comprises an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:1.

[0070] In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO:2. In certain embodiments, the heavy chain of the VEGF antibody comprises an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:2.

[0071] In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the VEGF antibody comprises the amino acid sequence set forth in SEQ ID NO:21.

[0072] In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the VEGF antibody comprises the amino acid sequence set forth in SEQ ID NO: 22.

[0073] In certain embodiments, the VEGF antibody binds to VEGF with an EC50 of about 75 picomolar or less. In certain embodiments, the VEGF antibody binds to VEGF with an EC50 of about 60 picomolar or less. In certain embodiments, the VEGF antibody binds to VEGF with an EC50 of about 50 picomolar or less. In certain embodiments, the VEGF antibody binds to VEGF with an EC50 of about 40 picomolar or less.

[0074] ANG-2 antibody Described herein are antibodies that bind to ANG-2 protein. In some embodiments, the ANG-2 protein is human ANG-2 protein.

[0075] In certain embodiments, described herein is an angiopoietin-2 (ANG-2) binding antibody or antigen-binding fragment thereof, wherein the antibody comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY), wherein the antibody binds to ANG-2.

[0076] In certain embodiments, described herein is an angiopoietin-2 (ANG-2)-binding antibody or antigen-binding fragment thereof, wherein the antibody binds to ANG-2.

[0077] In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 11. In a specific embodiment, the heavy chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:11.

[0078] In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the heavy chain of the ANG-2 antibody comprises an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:12.

[0079] In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 21. In certain embodiments, the light chain variable region of the ANG-2 antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 21. In a specific embodiment, the light chain variable region of the ANG-2 antibody comprises the amino acid sequence set forth in SEQ ID NO:21.

[0080] In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO: 22. In certain embodiments, the light chain of the ANG-2 antibody comprises the amino acid sequence set forth in SEQ ID NO: 22.

[0081] VEGF / ANG-2 bispecific antibody Described herein are bispecific antibodies that bind to VEGF and ANG-2 proteins. In some embodiments, the VEGF and / or ANG-2 proteins are human VEGF or ANG-2 proteins. The bispecific antibodies of the present disclosure are in a common light chain format, in which the heavy chain of the VEGF-binding moiety is different from the heavy chain of the ANG-2-binding moiety, and a common light chain is used that can be linked to either heavy chain. This format prevents undesired heavy and light chain pairing (because only one type of light chain is present) and makes antibody formation more efficient during production. The resulting antibody contains two heavy chains and two light chains arranged as a classical antibody (except that the two heavy chains form heterodimers). To prevent undesired heavy chain homodimerization (e.g., two anti-ANG-2 heavy chains or two anti-VEGF heavy chains), the heavy chain can further include mutations or substitutions in the heavy chain constant region to promote proper heterodimer formation.

[0082] A common light chain bispecific structure can include first and second heavy chain molecules that further include mutations in the CH3 domain that facilitate binding of the first and second heavy chains and / or prevent binding of a first heavy chain to another first heavy chain or a second heavy chain to another second heavy chain. The mutations can prevent binding of two first heavy chain molecules or two second heavy chain molecules physically (e.g., steric hindrance, putting a "knob" into a "hole") or biochemically (e.g., electrostatic interactions). An exemplary knob-into-hole mutation includes T366W (EU numbering) in one heavy chain and T366S / L368A / Y407V (EU numbering) in the second heavy chain. Exemplary mutations that facilitate coupling of the first and second heavy chain molecules are disclosed, for example, in WO2009089004, U.S. Patent No. 8,642,745, US PG-PUB:US20140322756, and "The making of bispecific antibodies" MAbs. 2017 February-March;9(2):182-212.

[0083] The anti-VEGF / ANG-2 bispecific antibody may contain one or more substitutions to reduce effector function. Such substitutions result in a variant Fc molecule. In some embodiments, the variant Fc region is an IgG1 The Fc region includes one or more mutations, such as (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R, (k) 331S, (l ) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V, 238W or 238Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T or 254V, (p) 255N, (q) 256H, 256K, 256R or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y or 265A, (t) 267G, 267H, 2671 or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G or 311S, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373A, 373G or 373S, (kk) 376E, 376W or 376Y, (11)380D, (mm)382D or 382P, (nn)385P, (oo)424H, 424M or 424V, (pp)4341, (qq)438G, (rr)439E, 439H or 439Q, (ss)440A, 440D, 440E, 440F, 440M, 440T or 440V, (tt)K322A, (uu)L235E, (vv)L234A and L235A, (ww)L234A, L235A and G237A, (xx)L234A, L235A and P329G,(yy) L234F, L235E and P331S, (zz) L234A, L235E and G237A, (aaa), L234A, L235E, G237A and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S and P331S, (ccc) L234A, L235A and P329A, (ddd) G236R and L328R, (ee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G according to EU numbering, (kkk) D270A, (111) A330L, (mmm) P331A or P331S, or (nnn) E233P, (ooo) L234A, L235E, G237A, A330S, and P331S, or (ppp) any combination of (a) to (uu).

[0084] In certain embodiments, the bispecific antibody comprises a vascular endothelial growth factor (VEGF) binding portion comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY), and angiopoietin 2 (A

[0003] Described herein are bispecific antibodies that bind to VEGF and ANG-2, comprising an angiopoietin 2 (ANG-2) binding moiety, the bispecific antibody comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY).

[0085] In certain embodiments, the bispecific antibody comprises a vascular endothelial growth factor (VEGF) binding portion comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY); an angiopoietin 2 (ANG-2) binding portion comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), (b) the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY), and a light chain complementarity determining region 1 (LCDR1) comprising: (a) the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS), (b) the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK), and (c) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH), and the bispecific antibody binds to VEGF and ANG-2.

[0086] In certain embodiments, the bispecific antibody comprises a vascular endothelial growth factor (VEGF) binding portion comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT), (b) a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 4 (INPYNGNT), and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY); an angiopoietin 2 (ANG-2) binding portion comprising: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG), and (b) the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK). and (c) a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY), and a common light chain complementarity determining region 1 (LCDR1) comprising: (a) the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS), (b) the light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK), and (c) a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH), and the bispecific antibody binds to VEGF and ANG-2.

[0087]

[0013] In certain embodiments, described herein are bispecific antibodies that bind to VEGF and ANG-2, comprising: (a) a first heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 1; (b) a second heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 11; and (c) a common light chain variable region, wherein the light chain variable region comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identity to the amino acid sequence set forth in SEQ ID NO: 21.

[0088] In certain embodiments, the VEGF / ANG-2 bispecific antibody comprises (a) a first heavy chain comprising an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain comprising a light chain comprising an amino acid sequence comprising at least 85% identity to the amino acid sequence set forth in SEQ ID NO:22, and binds to VEGF and ANG-2.

[0089] In certain embodiments, the VEGF / ANG-2 bispecific antibody comprises (a) a first heavy chain comprising an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain comprising a light chain comprising an amino acid sequence comprising at least 90% identity to the amino acid sequence set forth in SEQ ID NO:22, and binds to VEGF and ANG-2.

[0090] In certain embodiments, the VEGF / ANG-2 bispecific antibody comprises (a) a first heavy chain comprising an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain comprising a light chain comprising an amino acid sequence comprising at least 95% identity to the amino acid sequence set forth in SEQ ID NO:22, and binds to VEGF and ANG-2.

[0091] In certain embodiments, the VEGF / ANG-2 bispecific antibody comprises (a) a first heavy chain comprising an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain comprising a light chain comprising an amino acid sequence comprising at least 97% identity to the amino acid sequence set forth in SEQ ID NO:22, and binds to VEGF and ANG-2.

[0092] In certain embodiments, the VEGF / ANG-2 bispecific antibody comprises (a) a first heavy chain comprising an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain comprising a light chain comprising an amino acid sequence comprising at least 98% identity to the amino acid sequence set forth in SEQ ID NO:22, and binds to VEGF and ANG-2.

[0093] In certain embodiments, the VEGF / ANG-2 bispecific antibody comprises (a) a first heavy chain comprising an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO:2, (b) a second heavy chain comprising an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO:12, and (c) a common light chain comprising a light chain comprising an amino acid sequence comprising at least 99% identity to the amino acid sequence set forth in SEQ ID NO:22, and binds to VEGF and ANG-2.

[0094] In certain embodiments, the bispecific antibody comprises (a) a first heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 2, (b) a second heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 12, and (c) a common light chain, including a light chain comprising that set forth in SEQ ID NO: 22, and binds to VEGF and ANG-2.

[0095] Treatment method In certain embodiments, antibodies useful for treating ocular diseases are disclosed herein. In certain embodiments, the ocular disease is associated with age or another comorbidity, such as diabetes. In certain embodiments, the ocular disease is macular degeneration, in certain embodiments, the macular degeneration is age-related, in certain embodiments, the macular degeneration is diabetes-related, in certain embodiments, the macular degeneration is wet macular degeneration, in certain embodiments, the ocular disease is branch retinal vein occlusion, and in certain embodiments, the ocular disease is central retinal vein occlusion.

[0096] In certain embodiments, the antibody can be administered to a subject in need thereof by any route suitable for administering an antibody-containing pharmaceutical composition, such as, for example, topically, subcutaneously, intravenously, or intravitreally. In certain embodiments, the antibody or pharmaceutical composition comprising the antibody is administered topically. In certain embodiments, the antibody or pharmaceutical composition comprising the antibody is administered subcutaneously. In certain embodiments, the antibody or pharmaceutical composition comprising the antibody is administered intravenously. In certain embodiments, the antibody or pharmaceutical composition comprising the antibody is administered intravitreally.

[0097] In certain embodiments, the antibody is administered according to a suitable dosing schedule, such as weekly, twice weekly, monthly, twice monthly, once every two weeks, once every three weeks, or once every month, once every two months, once every three months, once every four months, once every five months, or once every six months. The antibody can be administered in any therapeutically effective amount. In certain embodiments, a pharmaceutically acceptable amount is about 0.1 mg / kg to about 50 mg / kg. In certain embodiments, a pharmaceutically acceptable amount is about 1 mg / kg to about 40 mg / kg. In certain embodiments, a pharmaceutically acceptable amount is about 1 mg / kg to about 20 mg / kg. In certain embodiments, a pharmaceutically acceptable amount is about 1 mg / kg to about 10 mg / kg. In certain embodiments, a pharmaceutically acceptable amount is about 5 mg / kg to about 30 mg / kg. In certain embodiments, a pharmaceutically acceptable amount is about 5 mg / kg to about 20 mg / kg. Intravitreal administration concentrations can range from 50 mg / ml to 150 mg / ml for intravitreal use. A therapeutically effective amount includes an amount sufficient to ameliorate one or more symptoms associated with the disease or affliction being treated.

[0098] Pharmaceutically Acceptable Excipients, Carriers, and Diluents In certain embodiments, the anti-VEGF / ANG-2 monospecific and bispecific antibodies of the present disclosure are included in pharmaceutical compositions containing one or more pharmaceutically acceptable excipients, carriers, and diluents. Pharmaceutically acceptable excipients, carriers, and diluents may be included to increase the shelf life, stability, or administrability of the antibody. Such compounds include salts, pH buffers, surfactants, anticoagulants, and preservatives. In certain embodiments, the antibodies of the present disclosure are administered suspended in a sterile solution. In certain embodiments, the solution contains about 0.9% NaCl. In certain embodiments, the solution contains about 5.0% dextrose. In certain embodiments, the solution further comprises one or more of a buffering agent, such as acetate, citrate, histidine, succinate, phosphate, bicarbonate, and hydroxymethylaminomethane (Tris); a surfactant, such as polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), and poloxamer 188; a polyol / disaccharide / polysaccharide, such as glucose, dextrose, mannose, mannitol, sorbitol, sucrose, trehalose, and dextran 40; an amino acid, such as glycine or arginine; an antioxidant, such as ascorbic acid, methionine; or a chelating agent, such as EDTA or EGTA.

[0099] In certain embodiments, antibodies of the present disclosure may be shipped / stored, lyophilized, and reconstituted prior to administration. In certain embodiments, lyophilized antibody formulations include bulking agents such as mannitol, sorbitol, sucrose, trehalose, dextran 40, or combinations thereof. The lyophilized formulation may be contained in a vial made of glass or other suitable non-reactive material. When formulated, antibodies, whether reconstituted or not, may be buffered at a specific pH, generally below 7.0. In certain embodiments, the pH may be 4.5-7.0, 4.5-6.5, 4.5-6.0, 4.5-5.5, 4.5-5.0, or 5.0-6.0.

[0100] Further described herein are kits comprising one or more of the antibodies described herein in a suitable container and one or more additional components selected from the following: instructions for use; diluents, excipients, carriers, and devices for administration.

[0101] In certain embodiments, methods for preparing eye disease treatments are described herein, comprising mixing one or more pharmaceutically acceptable excipients, carriers, or diluents with an antibody of the present disclosure. In certain embodiments, methods for preparing cancer treatments for storage or transportation are described herein, comprising lyophilizing one or more antibodies of the present disclosure. [Example]

[0102] The following illustrative examples are representative of embodiments of the compositions and methods described herein and are not meant to be limiting in any way.

[0103] Example 1 - Generation of VEGF / ANG-2 bispecific surrobodies Nucleic acid sequences encoding sequences corresponding to SEQ ID NO:2, SEQ ID NO:12, and SEQ ID NO:22 were cloned into a plasmid vector to induce eukaryotic cell expression. Three expression plasmids were constructed. The first plasmid contained one copy each of the surrogate light chain (SLC), the VEGF-specific Knob heavy chain, and the ANG-2-specific Hole heavy chain. The second plasmid contained two copies of SLC and one copy of each heavy chain in the orientation SLC:HC-Knob:HC:Hole:SLC. The third plasmid contained two copies of SLC and one copy of each heavy chain in the orientation SLC:SLC-:HC-Knob:HC:Hole. The products expressed and purified from the three stable cell lines ("RO-101") were designated Sample 1, Sample 2, and Sample 3.

[0104] CHO cells were cultured in CD-CHO medium (Life Technologies) supplemented with 6 mM L-glutamine (Life Technologies). Cells were incubated in a shaking incubator at 36.5°C, 5% CO2, and 140 rpm.

[0105] Gene expression plasmids were prepared for transfection by linearization, followed by ethanol precipitation and resuspension in EB buffer to a final concentration of 400 μg / ml. Transfections were performed by electroporation using Gene Pulse XCell. For each transfection, 1.43 x 10 cells were transfected in prewarmed CD-CHO medium. 7 Viable cells were resuspended at 100 μl / ml. 100 μl of linearized DNA at a concentration of 400 μg / ml was dispensed into a 0.4 cm gap electroporation cuvette, and 700 μl of cell suspension was added. Three cuvettes of cells and DNA were electroporated at 300 V and 900 μF and immediately transferred to 30 ml of pre-warmed CD-CHO medium supplemented with 10 ml / L SP4 to generate stable pools. Selected stable transfectants were expanded, and surrobodies were isolated from the supernatant by Protein A chromatography. A secondary polishing step was performed to remove undesired fractions, i.e., aggregates. The purified protein was then analyzed by SE-HPLC and SDS-PAGE.

[0106] Reduced and non-reduced samples of RO-101 were electrophoresed for SDS-PAGE analysis. Figure 1A confirms the presence of the product, and a good level of purity was observed. Under non-reducing conditions, multiple protein bands between 100 and 150 kDa were observed for the product (Figure 1A: lanes 3-5). Under reducing conditions, bands corresponding to the molecular weights of the light chain (~25 kDa) and heavy chain (~50 kDa) were observed, as expected for all three products (Figure 1A: lanes 7-9). The purified RO-101 protein was also analyzed by SE-HPLC. All three sample proteins showed a single peak of 100% purity (see Figure 1B).

[0107] Example 2 - Binding of VEGF / ANG-2 bispecific surrobodies Surobodies RO-101 prepared according to Example 1 were tested for their binding ability to target antigens.

[0108] VEGF ELISA-Recombinant Human VEGF 165 Plates were coated at 1 μg / mL using ELISA kits (Peprotech, catalog number 100-20). The product was diluted in blocking buffer to a starting concentration of 100 nM, and then 1:3 dilutions were tested. Binding was detected with an HRP-conjugated donkey anti-human IgG Fcγ antibody (Jackson ImmunoResearch Laboratories, catalog number 709-035-098). Herceptin was used as a nonspecific control that did not bind. Faricimab and aflibercept were run in parallel with the product as reference materials. The results are shown in Table 1. The results demonstrated high binding affinity for the product with EC50 values of 0.040-0.056 nM, which was comparable to or slightly better than binding with the faricimab and aflibercept reference materials.

[0109] [Table 1]

[0110] ANG-2 ELISA: Recombinant human ANG-2 (R&D Systems, catalog number 623-AN-025 / CF) was used to coat plates at 1 μg / mL. The product was diluted in blocking buffer at a starting concentration of 100 nM, and then 1:3 dilutions were tested. Binding was detected with an HRP-conjugated donkey anti-human IgG Fcγ antibody (Jackson ImmunoResearch Laboratories, catalog number 709-035-098). Herceptin was used as a nonspecific control that did not bind. The results are shown in Table 2. The results showed high binding affinity for the product with EC50 values of 0.045 to 0.054 nM, while faricimab showed significantly lower binding affinity, and the aflibercept control showed no binding at all.

[0111] [Table 2]

[0112] Therefore, the tested bispecific RO-101 surrobody exhibited a potent inhibitory effect on rhVEGF compared to existing VEGF antibodies or fusion proteins of the extracellular domains of human VEGFR1 and VEGFR2. 165 showed similar affinity for ANG-1 and much superior affinity for ANG-2 (e.g., 42- to 65-fold increase in binding affinity).

[0113] Example 3 - VEGF Binding ELISA and Inhibition of VEGF Receptor Binding The surrobody product RO-101 was tested for its binding to different isoforms of VEGF and its inhibition of VEGF receptor interaction. 165 is the most abundant and potent isoform of VEGF-A, and VEGF 121 is the predominant isoform in the eye. Therefore, both isoforms were tested in the binding assay. 121 (rhVEGF 121 ") and recombinant human VEGF 165 (rhVEGF 165") was obtained from Peprotech (see Table 10). 121 contains a reserved platelet-derived growth factor (PDGF) domain without a heparin-binding domain and is freely diffusible.

[0114] Therefore, the RO-101_Sample 1 binding affinity was compared with that of VEGF 121 and VEGF 165 (See Figure 2B). 121 (Peprotech, Catalog No. 100-20A) and rhVEGF 165 (Peprotech, Cat. No. 100-20) was used to coat Corning 9017 medium-binding plates at 1 μg / mL and 100 μl / well. The product was diluted in blocking buffer at a starting concentration of 100 nM, and then 1:3 dilutions were tested. Donkey anti-human IgG Fcγ-HRP (Jackson ImmunoResearch Laboratories, Cat. No. 709-035-098) was used for detection and visualized with TMB substrate. OD450nm readings were measured using a Victor 3 (PerkinElmer 1420 Multilabel Counter).

[0115] [Table 3]

[0116] As shown in Figure 2B and Table 3, RO-101 binds rhVEGF with similar affinity. 121 and rhVEGF 165 Combine with.

[0117] RO-101_Sample 1 in the form of SgG1 was then tested against rhVEGF in an ELISA binding assay. 121 These were compared with faricimab (IgG1) in terms of their binding affinity to rhVEGF. 121Coming 9017 medium-binding plates were coated using RO-101. RO-101 was diluted in blocking buffer to a starting concentration of 10 nM, and then 1:3 dilutions were tested. Donkey anti-human IgG Fcγ-HRP (Jackson ImmunoResearch Laboratories, catalog number 709-035-098) was used for detection, and visualization was performed with TMB substrate. OD450nm readings were measured using a Victor3 (PerkinElmer 1420 Multilabel Counter).

[0118] [Table 4]

[0119] As shown in Figure 2C and Table 4, RO-101 and faricimab inhibited rhVEGF with similar affinities in ELISA. 121 Combine with.

[0120] RO-101_Sample 1 was then tested against rhVEGF in an ELISA binding assay. 165 These were compared with faricimab in terms of their binding affinity to VEGF. 165 Coming 9017 medium-binding plates were coated with RO-101. RO-101 was diluted in blocking buffer to a starting concentration of 10 nM, and then 1:3 dilutions were tested. Donkey anti-human IgG Fcγ-HRP (Jackson ImmunoResearch Laboratories, catalog number 709-035-098) was used for detection, and visualization was performed with TMB substrate. OD450nm readings were measured on a Victor 3 using a PerkinElmer 1420 Multilabel Counter.

[0121] [Table 5]

[0122] As shown in Figure 2D and Table 5, RO-101 and faricimab inhibited rhVEGF with similar affinities in ELISA. 165 Combine with.

[0123] Next, RO-101_Sample 1 was added to VEGF 165 The inhibitors were compared with faricimab for their inhibition of the interaction between rhVEGF R2 and VEGF receptor 2 (VEGF R2). VEGF R2 is also known as the kinase insert domain receptor (KDR). As shown in Figure 2E, 1:3 serial dilutions of RO-101 or faricimab, starting at 200 nM, were mixed at a 1:1 ratio with 2 nM biotinylated rhVEGF R2 / KDR receptor (AcroBiosystems, catalog number KDR-H82E5). The mixtures were then incubated with rhVEGF R2 / KDR receptor (AcroBiosystems, catalog number KDR-H82E5). 165 The antibody was added to an ELISA binding plate containing RO-101 or falcimab. Biotinylated rhVEGF R2 / KDR without RO-101 or falcimab was used as a binding control. Receptor binding was detected with HRP-conjugated streptavidin (Jackson ImmunoResearch Laboratories, Cat. No. 016-030-084) and visualized with TMB substrate. The results are shown in Figure 2F, and the corresponding IC50 values are shown in Table 6.

[0124] [Table 6]

[0125] As shown in Figure 2F and Table 6, RO-101_Sample 1 inhibited rhVEGF 165 It was over three times more potent than faricimab in inhibiting the interaction between rhVEGF R2 / KDR receptor and rhVEGF R2 / KDR receptor.

[0126] Example 4 - ANG-2 Binding ELISA and Inhibition of ANG-2 Receptor Binding The surrobody product RO-101 was tested for its binding to ANG-2 and its inhibition of the interaction between ANG-2 and its receptor.

[0127] RO-101_Sample 1 or RO-101 ("RO-101_LX") in concentrated solution was compared to faricimab for their binding affinity to rhANG-2 in an ELISA binding assay. rhANG-2 (AcroBioSystems, catalog number AN2-H52H4) was used to coat Corning 9017 media-binding plates. RO-101 was diluted in blocking buffer at a starting concentration of 100 nM, and then 1:3 dilutions were tested. Donkey anti-human IgG Fcγ-HRP (Jackson ImmunoResearch Laboratories, catalog number 709-035-098) was used for detection, and visualization was performed with TMB substrate. OD450nm readings were measured by Victor 3 using a PerkinElmer 1420 Multilabel Counter.

[0128] [Table 7]

[0129] As shown in Figure 3A and Table 7, the binding affinity of RO-101 for rhANG-2 was 53-fold stronger than faricimab in ELISA, a significant improvement over faricimab by increasing binding to one of the two antigens.

[0130] Importantly, similar ELISA binding experiments were performed by independent teams with similar results. The EC50 values for RO-101 were 0.0526, 0.0498, and 0.0449 nM, with a mean value of 0.0491 nM. On the other hand, the EC50 values for faricimab were 3.508, 3.129, and 1.918 nM, with a mean value of 2.8517 nM. Thus, RO-101 binding to rhANG-2 was 58-fold better than faricimab in different experimental settings. This further confirmed that the binding affinity of RO-101 for ANG-2 is significantly better than that of faricimab.

[0131] Next, RO-101_Sample 1 was compared with faricimab for its inhibition of the interaction of human ANG-2 with the ANG-2 receptor tyrosine kinase Tie-2 (Tie-2). Serial dilutions of RO-101 or faricimab, starting at 200 nM, were mixed at a 1:1 ratio with 2 nM His-tagged rhANG-2 (AcroBiosystems, catalog no. AN2-H52H4). rhANG-2-His without RO-101 or faricimab served as a binding control. As shown in Figure 3B, RO-101 or faricimab was added to an ELISA binding plate with a recombinant human Tie-2-Fc coating (AcroBiosystems, catalog no. TI2-H5255). Binding of rhANG-2 to rhTie-2-Fc was detected by HRP-conjugated rabbit anti-His antibody (Bethyl Laboratories, catalog number A190-114P). The results are shown in Figure 3C, and the corresponding IC50 values are shown in Table 8.

[0132] [Table 8]

[0133] As shown in Figure 3C and Table 8, RO-101_sample 1 was over 17-fold more potent than faricimab in inhibiting the interaction between ANG-2 and the Tie-2 receptor.

[0134] In summary, RO-101 exhibited superior binding properties to rhANG-2 when compared with faricimab.

[0135] Example 5 - Binding Affinity of Different Forms of RO-101 VEGF-A-specific surrobody antigen-binding monomers (Sab), which are Fab equivalents, and single-chain fragments (scSv), which are scFv equivalents, derived from RO-101 were expressed in HEK293 cells. Specifically, the 50 kDa form of the surrobody, Sab, contained the VH-CH1 domain linked to VpreB, and the lambda 5 (surrogate light chain) scSV contained a single-chain fragment containing the VH domain bound to VpreB.

[0136] The resulting supernatant was purified by CaptureSelcet IgG-CH1 or Ni-NTA for His-tagged scSv protein. The three forms, along with RO-101 IgG, were purified by rhVEGF. 165 and rhANG-2, respectively.

[0137] RO-101 SgG1, Sab, and scSv were tested in duplicate. They were diluted in blocking buffer to a starting concentration of 10 nM, and then 1:3 dilutions were tested. rhVEGF 165 Binding ELISA was detected by biotinylated anti-human VpreB1 antibody and HRP-conjugated streptavidin.

[0138] [Table 9-1]

[0139] As shown in Figure 4A and Table 9.1, monomeric anti-VEGF-A Sab and scSv inhibited rhVEGF 165 Thus, all three forms of the VEGF-A specific surrobody bind to rhVEGF as well as to its SgG form. 165 The α- and β-glucan-binding proteins had similar binding affinities to α- and β-glucan-binding proteins.

[0140] RO-101 SgG1, Sab, and scSv were tested in duplicate. SgG1 was diluted in blocking buffer to a starting concentration of 10 nM. Sab and scSv were diluted in blocking buffer to a starting concentration of 100 nM. They were then serially diluted 1:3. ANG-2 binding ELISA was detected with biotinylated anti-human VpreB1 antibody and HRP-conjugated streptavidin.

[0141] [Table 9-2]

[0142] As shown in Figure 4B and Table 9.2, the monomeric anti-ANG-2 Sab and scSv bind well to ANG-2, with picomolar affinity for rhANG-2.

[0143] Example 6 - Binding of RO-101 to PDGF / VEGF family members PDGF / VEGF family members were obtained from three different suppliers: Peprotech, R&D Systems, and AcroBiosystems (see Table 10). Sequence alignment and analysis were performed (see Figure 5A). Specifically, the rhVEGF-B from Peprotech and R&D had identical sequences, whereas the rhVEGF-B sequence from AcroBiosystems had a different C-terminus. All three suppliers used the same rhVEGF-C sequence, except that the rhVEGF-C sequence from AcroBiosystems had an additional nine residues at the N-terminus. All three suppliers used the same rhVEGF-D sequence, except that the rhVEGF-D sequence from Peprotech had an additional four residues at the N-terminus and four residues at the C-terminus. The cross-reactivity of RO-101 with placental growth factor-1 (P1GF-1) and placental growth factor-3 (P1GF-3), two additional human PDGF / VEGF family members containing the conserved cysteine knot domain, was also examined.

[0144] [Table 10]

[0145] First, binding to rhVEGF-B was investigated using rhVEGF 165 The study was compared with rhVEGF-B or rhVEGF 165 Corning 9017 medium binding plates were coated with 1 μg / mL and 100 μl / well using the same reagent. Product RO-101_Sample 1 was diluted in blocking buffer at a starting concentration of 100 nM, and then 1:3 dilutions were tested. Donkey anti-human IgG Fcγ-HRP was used for detection. OD450nm readings were measured by Victor 3.

[0146] [Table 11]

[0147] As shown in Figure 5B and Table 11, RO-101 showed little binding to rhVEGF-B at 100 nM.

[0148] Second, the binding of RO-101_Sample 1 to rhVEGF-C or rhVEGF-D was assessed using rhVEGF 165 rhVEGF-C and rhVEGF-D were obtained from AcroBiosystems. 165 was obtained from Peprotech and served as a positive control. Different target proteins were used to coat Corning 9017 medium-binding plates at 1 μg / mL and 100 μl / well. Donkey anti-human IgG Fcγ-HRP was used for detection. OD450nm readings were measured using a Victor 3.

[0149] [Table 12]

[0150] As shown in Figure 5C and Table 12, RO-101 did not bind to commercially available rhVEGF-C or rhVEGF-D proteins that contain only the PDGF domain.

[0151] Third, binding to rhPIGF-1 or rhPIGF-3 was assessed using rhVEGF 165 The target protein was used to coat Coming 9017 medium-binding plates at 1 μg / mL and 100 μl / well. Product RO-101_Sample 1 was diluted in blocking buffer at a starting concentration of 100 nM, and then 1:3 dilutions were tested. Donkey anti-human IgG Fcγ-HRP was used for detection. OD450nm readings were measured on a Victor 3.

[0152] [Table 13]

[0153] As shown in Figure 5D and Table 13, RO-101 did not bind to PIGF-1 at >100 nM and bound weakly to PIGF-3.

[0154] Example 7 - Binding of RO-101 to cross-species VEGF-A and ANG-2 RO-101 was synthesized from VEGF from different species. 165 and ANG-2 orthologues (see Table 14). Sequence alignments (see Figure 6A for VEGF and Figure 6C for ANG-2) and homology comparisons (see Table 15.1 for VEGF and Table 15.2 for ANG-2) were performed.

[0155] [Table 14]

[0156] [Table 15-1]

[0157] [Table 15-2]

[0158] Similar binding assays were performed as described in the previous examples. Figure 6B and Table 16 show that RO-101 binds to rabbit, dog, and pig VEGF-A targets with comparable affinity when compared to the binding of human VEGF-A.

[0159] [Table 16]

[0160] Similarly, Figure 6D and Table 17 show that RO-101 binds to rabbit and targets canine ANG-2 with affinity comparable to human ANG-2.

[0161] [Table 17]

[0162] Taken together, RO-101 displayed similarly strong binding affinity to VEGF and ANG-2 orthologues across several species.

[0163] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention. It will be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention.

[0164] All publications, patent applications, issued patents, and other documents mentioned herein are incorporated by reference herein as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in texts incorporated by reference are excluded to the extent they conflict with definitions in this disclosure.

[0165] [Table 18-1]

[0166] [Table 18-2]

Claims

1. A vascular endothelial growth factor A (VEGF_A) binding antibody or antigen-binding fragment thereof, a. a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT); b. a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence (INPYNGNT) set forth in SEQ ID NO:4, and c. A heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO:5 (AKAPAVFWWTGLDY); The antibody is a vascular endothelial growth factor A (VEGF_A) binding antibody or an antigen-binding fragment thereof that binds to VEGF_A.

2. The antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain variable region comprising an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:

1.

3. 3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising a heavy chain constant region comprising an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:

2.

4. 4. The antibody or antigen-binding fragment thereof of claim 1, further comprising a surrogate light chain.

5. the surrogate light chain a. a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS); b. a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK); and c) The antibody or antigen-binding fragment thereof of claim 4, comprising a light chain complementarity-determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH).

6. 6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, comprising a light chain variable region comprising an amino acid sequence that comprises at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

21.

7. 7. The antibody or antigen-binding fragment thereof of any one of claims 1 to 6, comprising a light chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

22.

8. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein the antibody binds to a peptide comprising the platelet-derived growth factor (PDGF) domain of VEGF-A.

9. The antibody or antigen-binding fragment thereof according to claim 8, wherein the PDGF domain of VEGF_A comprises a fragment of VEGF_A ranging from amino acid 50 to 132.

10. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, wherein the antibody binds to a peptide comprising the VEGF-C heparin domain of VEGF-A.

11. The antibody or antigen-binding fragment thereof of claim 10, wherein the VEGF_C heparin domain of VEGF_A comprises a fragment of VEGF-A ranging from amino acid 143 to amino acid 191.

12. The antibody or antigen-binding fragment thereof of any one of claims 1 to 11, wherein the antibody binds to VEGF-A or a fragment thereof.

13. The antibody or antigen-binding fragment thereof of claim 12, wherein the antibody binds to VEGF_A or a fragment thereof with an EC50 of about 60 picomolar or less.

14. The antibody or antigen-binding fragment thereof of any one of claims 1 to 13, wherein the antibody inhibits the interaction of VEGF-A or a fragment thereof with a VEGF receptor.

15. The antibody or antigen-binding fragment thereof of claim 14, wherein the antibody inhibits the interaction of VEGF_A or a fragment thereof with the VEGF receptor with an IC50 of about 2000 picomolar or less.

16. The antibody or antigen-binding fragment thereof of claim 14, wherein the antibody inhibits the interaction of VEGF_A or a fragment thereof with the VEGF receptor at least three times more potently than faricimab inhibits the interaction.

17. The antibody or antigen-binding fragment thereof according to claim 16, wherein the VEGF receptor is VEGF receptor 2 / kinase insert domain receptor (KDR).

18. An angiopoietin-2 (ANG-2) binding antibody or antigen-binding fragment thereof, a. heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG); b. a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK); and c. A heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY); The antibody is an angiopoietin 2 (ANG-2) binding antibody or an antigen-binding fragment thereof that binds to ANG-2.

19. 19. The antibody or antigen-binding fragment thereof of claim 18, comprising a heavy chain variable region comprising an amino acid sequence that comprises at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

11.

20. 20. The antibody or antigen-binding fragment thereof of claim 18 or 19, comprising a heavy chain constant region comprising an amino acid sequence that comprises at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

12.

21. 21. The antibody or antigen-binding fragment thereof of any one of claims 18 to 20, further comprising a surrogate light chain.

22. the surrogate light chain a. a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS); b. a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK); and c) The antibody or antigen-binding fragment thereof of claim 21, comprising a light chain complementarity-determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH).

23. 23. The antibody or antigen-binding fragment thereof of any one of claims 18 to 22, comprising a light chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

21.

24. 24. The antibody or antigen-binding fragment thereof of any one of claims 18 to 23, comprising a light chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

22.

25. 25. The antibody or antigen-binding fragment thereof of any one of claims 18 to 24, wherein the antibody binds to ANG-2.

26. 26. The antibody or antigen-binding fragment thereof of claim 25, wherein the antibody binds to ANG-2 with an EC50 of about 55 picomolar or less.

27. 27. The antibody or antigen-binding fragment thereof of any one of claims 18 to 26, wherein the antibody binds to ANG-2 at least 50 times more strongly than faricimab binds to ANG-2.

28. 28. The antibody or antigen-binding fragment thereof of any one of claims 18 to 27, wherein the antibody inhibits the interaction of ANG-2 with an ANG-2 receptor.

29. 29. The antibody or antigen-binding fragment thereof of claim 28, wherein the antibody inhibits the interaction of ANG-2 with the ANG-2 receptor with an IC50 of about 800 picomolar or less.

30. 29. The antibody or antigen-binding fragment thereof of claim 28, wherein the antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at least 15-fold more potently than faricimab.

31. The antibody or antigen-binding fragment thereof according to any one of claims 28 to 30, wherein the ANG-2 receptor is a tyrosine kinase having immunoglobulin-like and EGF-like domain 2 receptor (Tie-2 receptor).

32. 32. The antibody or antigen-binding fragment thereof of any one of claims 1 to 31, wherein the antibody is an IgG antibody.

33. The antigen-binding fragment is Fab, F(ab) ２ 32. The antibody or antigen-binding fragment thereof of any one of claims 1 to 31, which is a single domain antibody or a single chain variable fragment (scFv).

34. 32. The antibody or antigen-binding fragment thereof of any one of claims 1 to 31, wherein the antibody is a surrobody and the antigen-binding fragment thereof is a surrobody antigen-binding fragment (Sab) or a single-chain variable fragment of a surrobody (scSv).

35. 35. The antibody or antigen-binding fragment thereof of any one of claims 1 to 34, wherein the antibody or antigen-binding fragment thereof is human, chimeric, or humanized.

36. 35. The antibody or antigen-binding fragment thereof of any one of claims 1 to 34, wherein the antibody or antigen-binding fragment thereof is humanized.

37. 37. A pharmaceutical composition comprising the antibody of any one of claims 1 to 36 and a pharmaceutically acceptable carrier, excipient, or diluent.

38. 38. The pharmaceutical composition of claim 37, formulated for intravenous administration.

39. 38. The pharmaceutical composition of claim 37, formulated for intravitreal administration.

40. A nucleic acid encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 36.

41. 41. An expression vector comprising the nucleic acid of claim 40.

42. 42. The expression vector of claim 41, wherein the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector.

43. 43. The expression vector of claim 41 or 42, wherein the expression vector is formulated for intravenous administration.

44. 43. The expression vector of claim 41 or 42, wherein the expression vector is formulated for intravitreal administration.

45. 45. A cell comprising a nucleic acid according to claim 40 or an expression vector according to any one of claims 41 to 44.

46. 46. The cell of claim 45, wherein the cell is a eukaryotic cell suitable for antibody production, optionally wherein the cell is a Chinese hamster ovary (CHO) cell.

47. A bispecific antibody, A vascular endothelial growth factor A (VEGF_A) binding moiety, a. a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 3 (GYTFSIYT); b. a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence (INPYNGNT) set forth in SEQ ID NO:4, and c. a vascular endothelial growth factor A (VEGF_A) binding portion comprising a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 5 (AKAPAVFWWTGLDY); and An angiopoietin-2 (ANG-2) binding moiety, a. heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 13 (GFTFSSYG); b. a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 14 (ISADSGDK); and c. An angiopoietin 2 (ANG-2) binding portion comprising a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 15 (AKEFISWIYTFDYLDY); A bispecific antibody that binds to VEGF_A and ANG-2.

48. 48. The bispecific antibody of claim 47, wherein the VEGF_A binding portion comprises a heavy chain variable region comprising an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:

1.

49. 49. The bispecific antibody of claim 47 or 48, wherein the VEGF_A binding portion further comprises a heavy chain constant region.

50. 50. The bispecific antibody of claim 49, wherein the heavy chain constant region comprises an engineered protuberance or an engineered cavity such that homodimerization of the VEGF_A binding portion is inhibited.

51. 51. The bispecific antibody of claim 50, wherein the engineered protuberance comprises a T366W substitution according to EU numbering.

52. 52. The bispecific antibody of claim 50 or 51 , wherein the engineered cavity comprises T366S / L368A / Y407V substitutions according to EU numbering.

53. 53. The bispecific antibody of any one of claims 49 to 52, wherein the heavy chain constant region comprises one or more substitutions relative to the Fc region that reduce antibody effector function.

54. 54. The bispecific antibody of claim 53, wherein the one or more substitutions made to the Fc region that reduce antibody effector function comprise L234A and / or L235A according to EU numbering.

55. 55. The bispecific antibody of any one of claims 49 to 54, wherein the heavy chain constant region comprises one or more substitutions of cysteine residues.

56. 56. The bispecific antibody of claim 55, wherein the one or more substitutions of a cysteine residue are at serine 354 according to EU numbering.

57. 57. The bispecific antibody of any one of claims 47 to 56, wherein the VEGF_A binding portion comprises a heavy chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

2.

58. 58. The bispecific antibody of any one of claims 47 to 57, wherein the bispecific antibody binds to a peptide comprising the platelet-derived growth factor (PDGF) domain of VEGF_A.

59. 59. The bispecific antibody of claim 58, wherein the PDGF domain of VEGF_A comprises a fragment of VEGF_A ranging from amino acid 50 to amino acid 132.

60. 60. The bispecific antibody of any one of claims 47 to 59, wherein the bispecific antibody binds to a peptide comprising the VEGF-C heparin domain of VEGF_A.

61. 61. The bispecific antibody of claim 60, wherein the VEGF_C heparin domain of VEGF_A comprises a fragment of VEGF-A ranging from amino acids 143 to 191.

62. 62. The bispecific antibody of any one of claims 47 to 61, wherein the bispecific antibody binds to VEGF-A or a fragment thereof.

63. 63. The bispecific antibody of claim 62, wherein the bispecific antibody binds to VEGF_A or a fragment thereof with an EC50 of about 60 picomolar or less.

64. 64. The bispecific antibody of any one of claims 47 to 63, wherein the bispecific antibody inhibits the interaction of VEGF_A or a fragment thereof with a VEGF receptor.

65. 65. The bispecific antibody of claim 64, wherein the bispecific antibody inhibits the interaction of VEGF_A or a fragment thereof with the VEGF receptor with an IC50 of about 2000 picomolar or less.

66. 65. The bispecific antibody of claim 64, wherein the bispecific antibody inhibits the interaction of VEGF_A or a fragment thereof with the VEGF receptor at least three times more potently than faricimab inhibits the interaction.

67. 67. The bispecific antibody of claim 66, wherein the VEGF receptor is VEGF receptor 2 / kinase insert domain receptor (KDR).

68. 68. The bispecific antibody of any one of claims 47 to 67, wherein the ANG-2 binding portion comprises a heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

11.

69. 69. The bispecific antibody of any one of claims 47 to 68, wherein the ANG-2 binding portion further comprises a heavy chain constant region.

70. 70. The bispecific antibody of claim 69, wherein the heavy chain constant region comprises an engineered protuberance or an engineered cavity such that homodimerization of the ANG-2 binding moiety is inhibited.

71. 71. The bispecific antibody of claim 70, wherein the engineered protuberance comprises a T366W substitution according to EU numbering.

72. 72. The bispecific antibody of claim 70 or 71, wherein the engineered cavity comprises T366S / L368A / Y407V substitutions according to EU numbering.

73. 73. The bispecific antibody of any one of claims 69 to 72, wherein the heavy chain constant region comprises one or more substitutions relative to the Fc region that reduce antibody effector function.

74. 74. The bispecific antibody of claim 73, wherein the one or more substitutions made to the Fc region that reduce antibody effector function comprise L234A and / or L235A according to EU numbering.

75. 75. The bispecific antibody of any one of claims 69 to 74, wherein the heavy chain constant region comprises one or more substitutions of cysteine residues.

76. 76. The bispecific antibody of claim 75, wherein said one or more substitutions of a cysteine residue are at serine 354 according to EU numbering.

77. 77. The bispecific antibody of any one of claims 47 to 76, wherein the ANG-2 binding portion comprises a heavy chain constant region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

12.

78. 78. The bispecific antibody of any one of claims 47 to 77, wherein the bispecific antibody binds to ANG-2.

79. 79. The bispecific antibody of claim 78, wherein the bispecific antibody binds to ANG-2 with an EC50 of about 55 picomolar or less.

80. 80. The bispecific antibody of any one of claims 47 to 79, wherein the bispecific antibody binds to ANG-2 at least 50 times stronger than faricimab binds to ANG-2.

81. 81. The bispecific antibody of any one of claims 47 to 80, wherein the bispecific antibody inhibits the interaction of ANG-2 with an ANG-2 receptor.

82. 82. The bispecific antibody of claim 81, wherein said bispecific antibody inhibits the interaction of ANG-2 with said ANG-2 receptor with an IC50 of about 800 picomolar or less.

83. 82. The bispecific antibody of claim 81, wherein the bispecific antibody inhibits the interaction of ANG-2 with the ANG-2 receptor at least 15-fold more potently than faricimab.

84. 84. The bispecific antibody of any one of claims 81 to 83, wherein the ANG-2 receptor is a tyrosine kinase with immunoglobulin-like and EGF-like domain 2 receptor (Tie-2 receptor).

85. 85. The bispecific antibody of any one of claims 47 to 84, further comprising a common light chain.

86. 86. The bispecific antibody of claim 85, wherein the common light chain is a surrogate light chain.

87. the surrogate light chain a. a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 23 (NDHDIGVYS); b. a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 24 (YFSQSDK); and c) The bispecific antibody of claim 86, comprising a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 25 (AMGARSSVTH).

88. 88. The bispecific antibody of any one of claims 86 to 87, wherein the surrogate light chain comprises a light chain variable region comprising an amino acid sequence that comprises at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

21.

89. 68. The bispecific antibody of any one of claims 47 to 67, wherein the surrogate light chain comprises a light chain constant region comprising an amino acid sequence that comprises at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

22.

90. 1. A bispecific antibody or antigen-binding peptide, comprising: (a) a first heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 1; (b) a second heavy chain variable region comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 11; and (c) a common light chain variable region, wherein the common light chain variable region comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 21; wherein the bispecific antibody binds to VEGF_A and ANG-2.

91. 1. A bispecific antibody that binds to VEGF_A and ANG-2, comprising: (a) a first heavy chain comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 2; (b) a second heavy chain comprising an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 12; and (c) a common light chain, wherein the light chain comprises an amino acid sequence comprising at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO:

22.

92. 1. A bispecific antibody comprising: (a) a first heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 2; (b) a second heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 12; and (c) a common light chain, wherein the common light chain comprises the light chain set forth in SEQ ID NO: 22; and wherein the bispecific antibody binds to VEGF-A and ANG-2.

93. 93. A pharmaceutical composition comprising the bispecific antibody of any one of claims 47 to 92 and a pharmaceutically acceptable carrier, excipient, or diluent.

94. 94. The pharmaceutical composition of claim 93, formulated for intravenous administration.

95. 94. The pharmaceutical composition of claim 93, formulated for intravitreal administration.

96. 93. A nucleic acid or nucleic acids encoding the bispecific antibody of any one of claims 47 to 92.

97. 97. An expression vector comprising the nucleic acid of claim 96.

98. 98. The expression vector of claim 97, wherein the expression vector is a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, or a plasmid vector.

99. 99. The expression vector of claim 97 or 98, wherein the expression vector is formulated for intravenous administration.

100. 99. The expression vector of claim 97 or 98, wherein the expression vector is formulated for intravitreal administration.

101. 101. A pharmaceutical composition comprising a nucleic acid or nucleic acids encoding the bispecific antibody of any one of claims 96 to 100 and a pharmaceutically acceptable carrier, excipient, or diluent.

102. 102. The pharmaceutical composition of claim 101, formulated for intravenous administration.

103. 102. The pharmaceutical composition of claim 101, formulated for intravitreal administration.

104. 104. A method of treating an eye disease in an individual, comprising administering to the individual the antibody, bispecific antibody, nucleic acid or nucleic acids encoding said antibody or bispecific antibody, or pharmaceutical composition of any one of claims 1 to 103, thereby treating the eye disease.

105. 105. The method of claim 104, wherein the eye disease is macular degeneration.

106. 106. The method of claim 105, wherein the macular degeneration is age-related.

107. 106. The method of claim 105, wherein the macular degeneration is diabetes-related.

108. 106. The method of claim 105, wherein the macular degeneration is wet macular degeneration.

109. 105. The method of claim 104, wherein the eye disease is branch retinal vein occlusion.

110. 105. The method of claim 104, wherein the eye disease is central retinal vein occlusion.

111. 104. Use of an antibody, bispecific antibody, or pharmaceutical composition according to any one of claims 1 to 103 in a method for treating an eye disease.

112. 112. The use of claim 111, wherein the eye disease is macular degeneration.

113. The use of claim 112, wherein the macular degeneration is age-related.

114. The use of claim 112, wherein the macular degeneration is diabetes-related.

115. The use of claim 112, wherein the macular degeneration is wet macular degeneration.

116. 112. The use of claim 111, wherein the eye disease is branch retinal vein occlusion.

117. 112. The use of claim 111, wherein the eye disease is central retinal vein occlusion.

Images